

---

## Author Index to Volumes 24-29

---

Aamdahl S, 28:335  
Abe S, 29:191  
Abe T, 24:257; 25:375  
Adhvaryu SG, 27:33  
Adolph S, 26:235  
Ajmar F, 25:73; 25:265  
Akerman M, 25:55  
Alimena G, 26:5; 26:39;  
26:65; 27:21; 29:129  
Al Saadi A, 26:127  
Ambros P, 27:229; 29:315  
Amess J, 25:175  
Amess JAL, 28:287  
Amigo V, 26:171  
Andersson B, 27:349  
Andersson BS, 24:335  
Antony AC, 29:65  
Aoki N, 24:225  
Arai T, 24:359  
Arcese W, 26:5  
Archer SA, 24:271  
Arevalo M, 29:75  
Armitage JO, 25:219;  
27:335  
Arnold R, 26:51  
Arthur T, 27:345  
Arwert F, 25:37  
Atkin NB, 25:189; 26:355  
Aubert D, 28:119  
Audebert AA, 24:151  
Auerbach HE, 28:173  
Avanzi G, 29:57  
Avilés MJ, 29:75  
Ayuso C, 24:345  
Azar C, 25:367

Babinska M, 25:123  
Babu A, 24:367  
Baccarani M, 26:65  
Badia L, 26:171; 28:367  
Baglin TP, 27:167  
Bain S, 25:165

Baird M, 29:1  
Baker MC, 25:189; 26:355  
Bakhuis J, 27:21  
Bandini G, 26:5; 26:51  
Baranzelli MC, 25:371  
Barker PE, 25:379  
Barlogie B, 24:335;  
28:213  
Barry WE, 27:89  
Bartholdi MF, 27:273  
Bartnitzke S, 24:205;  
27:177  
Bartram CR, 26:235  
Baskin F, 28:163  
Bateman BJ, 25:219  
Battifora H, 29:303  
Bauters F, 24:355;  
25:103; 27:101;  
29:311  
Baylin SB, 25:27  
Becher R, 25:183; 26:51;  
26:217  
Behar C, 25:259  
Behm F, 24:87  
Behm FG, 27:251  
Beil B, 25:123  
Belch A, 27:135  
Bell DR, 25:141  
Bello C, 25:185  
Bello MJ, 25:355; 26:157;  
27:185; 28:187;  
29:75; 29:201;  
29:223; 29:323  
Bendix-Hansen K, 26:227  
Benet J, 29:91  
Benitez J, 24:345; 25:355;  
26:157; 26:199;  
27:185; 29:75; 29:201  
Benn P, 29:1  
Bennet K, 28:137  
Bennett DD, 25:97  
Bennett L, 29:1  
Beran M, 24:335, 27:349

Bergan A, 28:335  
Berger C, 29:1  
Berger CL, 28:267  
Berger R, 25:303; 26:117;  
27:79; 28:119;  
28:261; 28:293; 29:9  
Berman M, 25:361  
Bernhardt B, 29:1  
Bernheim A, 25:303;  
27:79; 28:261;  
28:293; 29:9  
Bernstein R, 24:137;  
24:213  
Bertini M, 29:57  
Bertoglio MG, 27:45  
Bessho F, 29:175  
Bettecken T, 24:191  
Bhagat SG, 28:163  
Bhargava MK, 24:263  
Bielawiec M, 24:363  
Bigner DD, 24:163;  
29:165  
Bigner SH, 24:163;  
29:165  
Billström R, 24:159;  
25:161; 26:65; 27:1;  
28:191; 29:129  
Bjerrum I, 28:107  
Blaise AM, 25:259  
Blake M, 27:51; 27:63  
Blick M, 27:349  
Blin N, 25:285  
Block AW, 29:135  
Boccaccio P, 25:73  
Boehm TLJ, 28:327  
Boiron M, 28:293  
Boixados JR, 26:157  
Bomirska A, 25:123  
Bonfil X, 29:91  
Bonti GV, 27:367  
Boogaerts, 26:5; 26:51  
Bordoni S, 27:367  
Borrello MG, 27:45

Bösch C, 24:205; 27:177  
 Bosly A, 28:113; 29:171  
 Boswell HS, 29:65  
 Bowcock AW, 24:137  
 Boyle PD, 26:261  
 Brasch J, 29:119  
 Brasch JM, 25:131  
 Brennan K, 27:161  
 Bridge JA, 29:97  
 Brieux de Salum S, 25:309  
 Brissaud P, 24:151  
 Brodeur GM, 28:55  
 Brodsky I, 26:15; 26:25  
 Broegger A, 28:335  
 Brøgger A, 24:327  
 Brooks VP, 26:299  
 Brothman AR, 26:287  
 Brothman LJ, 26:287  
 Brown JA, 27:251  
 Brox LW, 27:135  
 Bullerdiek J, 24:205; 27:177  
 Buonaguidi R, 27:145  
 Burns D, 28:163  
 Butler JJ, 24:7  
 Butler MG, 24:129; 28:253; 29:183  
 Butti G, 27:145  
 Buys CHCM, 27:361

Caballin MR, 29:91  
 Cabanillas F, 24:7  
 Cacciapaglio B, 29:1  
 Calabrese G, 29:261  
 Calebretta B, 27:89  
 Cao A, 27:219  
 Caporaso N, 24:299  
 Carbonell F, 26:5; 26:51; 26:65  
 Carloni I, 27:367  
 Carritt B, 27:361  
 Carroll AJ, 25:379  
 Carroll PR, 26:253  
 Carstens C, 25:285  
 Casalone R, 27:145; 29:253  
 Cascos AS, 24:345; 26:157  
 Cassel C, 24:11  
 Castoldi GL, 26:65; 26:75  
 Castro R, 27:51; 27:63  
 Cepulic M, 25:351; 28:353  
 Chaganti RSK, 26:253  
 Chang C, 26:279  
 Chattopadhyay SC, 29:109

Chen H, 28:301; 29:109  
 Chen TR, 24:95; 27:125  
 Chenevix-Trench G, 27:191; 27:251  
 Christiansen H, 26:235  
 Christensen IJ, 27:225  
 Clarke PT, 25:165  
 Cline M, 29:303  
 Coates PB, 25:165  
 Cobcroft RG, 28:87  
 Coleman M, 24:295; 29:1  
 Collins D, 27:345  
 Conde E, 25:185  
 Conti AF, 27:261  
 Cooper MD, 25:379  
 Cork A, 24:7; 28:213  
 Cosson A, 27:101  
 Cournoyer D, 27:73  
 Covello DA, 25:73  
 Cowan DH, 27:375  
 Cowan JM, 27:251  
 Cowell JK, 27:27  
 Cram LS, 26:287; 27:273  
 Criel A, 28:349  
 Crilley P, 26:25  
 Crossen PE, 28:93; 28:185  
 Cuiffo BP, 25:1  
 Cuneo A, 26:75  
 Czepulkowski B, 25:175; 28:287; 28:377

Dal Cin P, 26:271; 26:351; 26:377; 28:343  
 Dallapiccola B, 26:85  
 Danes BS, 26:261  
 Daniel M, 28:261; 28:293; 29:9  
 Darbyshire PJ, 28:377  
 Darrah J, 24:11  
 Dave BJ, 27:33  
 Davis RM, 28:163  
 Davoren B, 27:345  
 De Braekeleer M, 24:177; 27:135  
 Debray J, 24:151  
 Debruyne F, 29:23; 29:29  
 de Campos JM, 25:355; 26:157; 27:185; 28:187; 29:201; 29:223; 29:323  
 De Cuia MR, 26:39; 27:21  
 de Gramont A, 24:151  
 de Koning H, 25:37  
 de la Chapelle A, 25:87  
 Delannoy A, 27:39  
 De Laroque A, 27:371  
 Della Porta G, 27:45  
 Demaille MC, 25:371

Deminatti M, 24:355; 25:103; 25:371; 27:101; 29:311  
 den Dulk G, 24:231  
 de Pargament MM, 28:101  
 DeRiese W, 26:369  
 Derré J, 29:9  
 Deschamps M, 29:183  
 de Vinuesa ML, 28:101  
 De Virgiliis S, 27:219  
 Dewald GW, 27:73  
 Di Bartolomeo P, 26:51  
 Dieguez L, 26:171; 28:367  
 Diez E, 28:119  
 Diklic V, 28:183  
 Di Lernia R, 27:299  
 Dill FJ, 26:375  
 Dissing J, 26:143  
 Disteche CM, 25:271  
 Diverio D, 26:39; 27:21; 29:129  
 Dizon D, 28:213  
 Dolby TW, 24:17  
 Doneda L, 27:261; 27:299  
 Donselaar IG, 24:33  
 Donti R, 27:367  
 Dosik H, 24:295  
 Doyen C, 28:113; 29:171  
 Drabkowski D, 27:125  
 Dragani A, 29:261  
 Drahovsky D, 28:327  
 Dray C, 24:151  
 Dührsen C, 26:217  
 Duncan AMV, 25:169  
 Dutrillaux A, 25:7; 29:289  
 Dutrillaux B, 25:7; 29:289

Eaves CJ, 24:1  
 Edelson RL, 28:267  
 Egozcue J, 29:91  
 Eguchi M, 28:373  
 Eisenberg A, 29:1  
 Ekedahl C, 28:237  
 Elfenbein IB, 27:89  
 Emanuel BS, 25:369; 26:181; 29:159  
 Engert A, 26:363  
 Engquist L, 27:1  
 Estienne M, 29:311  
 Etches WS, 24:177

Faggionato F, 27:145  
 Fair WR, 26:253  
 Falchi AM, 27:219  
 Falini B, 27:367  
 Fan Y, 26:317; 29:135  
 Farrer LA, 27:327

Favrot M, 25:373  
Fayos JS, 26:199  
Fellin FM, 28:179  
Feminic-Kes R, 24:251; 25:351; 28:353  
Fenaux P, 24:355; 25:103; 29:311  
Fero ML, 26:245  
Ferrant A, 26:5; 26:51  
Ferstl G, 28:145  
Ferti-Passantonopoulou AD, 24:63; 27:289  
Filippetti A, 26:5; 26:51  
Fioritoni G, 29:261  
Fischer P, 28:145  
Fisher C, 26:179  
Fitchett M, 24:143  
Fitzgerald PH, 24:271  
Fitzgibbons RJ Jr, 28:245  
Flandrin G, 26:117; 28:261; 28:293; 29:9  
Fodstad Ø, 24:327  
Fonatsch C, 26:363  
Fong C, 28:55  
Forni E, 29:253  
Francart H, 25:233  
Franchi PG, 29:261  
Franke F, 26:235  
Francke U, 27:251  
Franssila K, 25:87  
Fraser C, 24:1; 29:103  
Frassoni F, 26:5; 26:51  
Freireich EJ, 28:213  
Frejo CM, 26:199  
Freter CE, 29:155  
Fujii H, 25:375  
Fuscaldo KE, 26:25; 26:65  
  
Gadner H, 27:229; 28:145  
Gaeta J, 28:343  
Gahrton G, 26:5; 26:51  
Gale RP, 29:245  
Galvin GP, 27:167  
Ganser A, 28:327  
Garaedts J, 29:23  
Gardet P, 25:303  
Garijo J, 25:185  
Garson OM, 27:111  
Garvin AJ, 25:97  
Gastaldi R, 26:39  
Gazdar A, 29:155  
Gedde-Dahl T, 24:327; 28:335  
Geelhoed GW, 24:11  
Geneix A, 27:371  
Genesca A, 29:91  
Geraci L, 29:261  
  
Geraedts J, 29:29  
Ghosh PK, 27:15  
Ghosh R, 27:15  
Giani S, 27:45  
Gibas L, 28:179  
Gibas Z, 25:21; 25:123; 25:369  
Gibbons B, 25:175; 28:287; 28:377  
Gilbert F, 24:75  
Gillespie DH, 26:15  
Giovinazzo G, 29:57  
Girodet J, 29:289  
Glick JH, 28:173  
Godwin JM, 28:93  
Gomis F, 28:367  
Goodacre A, 24:7; 24:335  
Goodfellow PJ, 27:327  
Goorha R, 27:251  
Gorman PA, 26:339  
Grabovskaya IL, 25:65  
Granata P, 27:145  
Greene MH, 24:299  
Griest A, 27:241  
Griffin CA, 25:369; 26:181  
Griffiths MJ, 24:143  
Grossman A, 28:163  
Gualandri V, 27:261  
Guerrasio A, 29:57  
Gutterman J, 27:349  
  
Haas OA, 26:5; 26:51; 27:229; 28:145; 29:315  
Habibian R, 29:271  
Hagemeijer A, 27:21  
Halbrecht T, 27:171  
Han T, 24:109  
Hanada R, 28:373; 29:175  
Hansen HE, 26:143  
Harbott J, 26:235  
Harris MG, 28:87  
Hay RJ, 27:125  
Hayashi Y, 28:373; 29:175  
Hayhoe FGJ, 28:145  
Hays T, 27:51; 27:63  
He XX, 27:135  
Heaton DC, 28:93  
Hecht BK, 26:95  
Hecht F, 24:189; 24:375; 25:293; 26:65; 26:95; 26:117; 26:175; 28:189; 29:187  
Heckl W, 24:191  
Heerema N, 29:65  
Heerema NA, 27:241  
Heil G, 28:327  
  
Heim S, 24:159; 24:319; 25:55; 28:137; 29:129  
Helsen C, 24:75  
Helson L, 24:75  
Henderson ES, 24:109  
Heuze F, 28:119  
Hill BT, 26:339  
Hill SM, 24:45  
Hirosawa S, 24:225  
Hirschfield L, 27:5  
Hoehn H, 24:191  
Hoelzer D, 28:327  
Hoffman R, 27:241; 29:65  
Holden JJA, 27:327; 29:139  
Holldack J, 26:363  
Hollings, PE, 24:271  
Hölzel F, 28:201  
Hoo J, 29:319  
Hori T, 25:81  
Horiike S, 24:257  
Horita Y, 29:109  
Horn HL, 28:185  
Horsman DE, 26:375  
Hossfeld DK, 26:59; 26:65  
Hough MR, 29:139  
House AK, 27:357  
Hovig E, 24:327  
Hsu TC, 28:5; 29:81  
Hu C, 26:279  
Hubbell HR, 24:17; 26:15  
Huben RP, 26:271  
Hulten MA, 24:45  
Hungerford J, 27:27  
  
Iacone A, 26:5  
Ichimaru M, 24:221; 29:327  
Inazawa J, 24:257  
Iriondo A, 25:185  
Ishibe T, 25:317  
Ishihara T, 25:81  
Israel MA, 24:119  
Ito H, 26:191  
Itoyama T, 29:327  
Ivan D, 28:353  
Iwabuchi H, 29:331  
  
Jackson L, 28:179  
Jagelman DG, 27:319  
Jäger U, 29:315  
Jani KH, 27:33  
Jarzabek V, 25:293  
Jaspers NGJ, 24:33  
Jay M, 27:27  
Jean P, 28:229  
Jelbart ME, 26:165  
Jenks H, 28:277

Jenkin DJ, 26:327; 27:357  
 Jhanwar S, 26:253  
 Joenje H, 25:37  
 Johansson B, 27:1; 28:137  
 Johnson DR, 27:335  
 Johnson S, 24:143  
 Jouet JP, 24:355; 25:103;  
     27:101; 29:311  
 Joseph GM, 24:129;  
     28:253  
 Jotereau F, 28:119

Kaczmarek L, 27:89  
 Kakati S, 26:271  
 Kalousek DK, 24:1;  
     26:375; 29:103  
 Kamakura M, 25:253  
 Kamihira S, 24:221  
 Kamiyama R, 24:225  
 Kaneko Y, 25:81; 26:309  
 Kang L, 26:279  
 Kant JA, 28:173  
 Kao-Shan CS, 24:119  
 Karpas A, 28:145  
 Kastelan M, 24:251  
 Kato A, 24:225  
 Katz R, 24:7  
 Keating A, 25:271  
 Keating M, 28:213  
 Keldsen N, 29:43  
 Kendal WS, 29:81  
 Kerndrup G, 26:227  
 Kida M, 25:253  
 Kidd JR, 27:327  
 Kidd KK, 27:327  
 Killough BW, 25:97  
 Kimberling WJ, 27:161  
 King CR, 27:345  
 Kinniburgh AJ, 25:15;  
     25:341; 26:105  
 Kinzler KW, 29:165  
 Kirkpatrick D, 28:155  
 Kirsch IR, 26:95  
 Kivi S, 28:77  
 Klar D, 27:171  
 Knapp W, 27:229  
 Knerich R, 27:145  
 Knospe WH, 25:361  
 Knutsen T, 29:155  
 Knuutila S, 25:87; 29:151  
 Kobylka P, 25:329  
 Koch H, 24:191  
 Köhler J, 24:191  
 Köller U, 27:229  
 Konja J, 24:251; 25:351;  
     28:353  
 Kopelovich L, 28:245  
 Kornmüller R, 27:229

Kosmo MA, 29:245  
 Kovacs G, 26:369; 28:363  
 Kovanen PE, 29:151  
 Kozlova TV, 25:65  
 Kraemer PM, 26:287;  
     27:273  
 Kristoffersson U, 24:159;  
     24:319; 25:55; 29:129  
 Krulik M, 24:151  
 Kubbies M, 24:191  
 Kubota K, 24:359  
 Kudo H, 24:225  
 Kühn D, 25:183  
 Kunzmann R, 28:201  
 Kurzrock R, 27:349  
 Kusak ME, 25:355;  
     27:185; 28:187;  
     29:201; 29:223;  
     29:323  
 Kuyl JM, 24:137

Laarakkers L, 29:29  
 Labal de Vinuesa M,  
     25:47; 28:357  
 LaGuette JG, 28:173  
 Lai JL, 24:355; 25:103;  
     25:371; 27:101;  
     29:311  
 Lambilotte A, 27:101  
 Lampert F, 26:235  
 Lange BJ, 29:179  
 Lanspa SJ, 28:245  
 Lanza F, 26:75  
 Larizza L, 27:261; 27:299  
 Larrakkers L, 29:23  
 Larripa I, 25:47; 28:101;  
     28:113; 28:357  
 Larsen JK, 27:225  
 Latimer F, 26:127  
 Lauer RC, 29:65  
 Le Coniat M, 25:303; 29:9  
 Lemieux N, 28:229  
 Le Pelley P, 24:355  
 Leung J, 28:155  
 Lewis JP, 28:277  
 Li FP, 24:11  
 Li P, 26:317  
 Li Y, 26:379  
 Lier ME, 28:335  
 Ligler FS, 26:25  
 Limon J, 25:123; 26:271;  
     28:343  
 Lin CC, 24:177; 27:135  
 Lin K, 29:331  
 Linder J, 27:335  
 Ling V, 25:141  
 Lister TA, 25:175; 28:287  
 Lizard-Nacol S, 25:373

Lombard M, 25:7  
 London B, 27:375  
 Lothe RA, 28:335  
 Louwagie A, 25:233;  
     27:39; 28:349  
 Lukasova M, 25:329  
 Lukeis R, 27:111  
 Lynch HT, 25:247;  
     27:161; 28:245  
 Lynch JF, 25:247; 27:161;  
     28:245

Macdougall LG, 24:213  
 Macera MJ, 24:367  
 Macrae FA, 27:111  
 Macy M, 27:125  
 Madercic M, 26:127  
 Madvedeva NV, 25:65  
 Maeda S, 28:301; 29:109  
 Magnani I, 27:299  
 Majdic O, 27:229  
 Makarkina GN, 25:65  
 Malay MAL, 27:357  
 Malet P, 27:371  
 Mamaev NN, 25:65  
 Mamaeva S, 28:311  
 Mamaeva SE, 25:65  
 Mandahl N, 24:159;  
     24:319; 25:55;  
     28:137; 29:129  
 Manning J, 24:7  
 Manolov G, 28:145  
 Manolova Y, 28:145  
 Marcus JN, 28:245  
 Mark J, 24:163; 28:237;  
     29:165  
 Markkanen A, 25:87  
 Marynets OV, 25:65  
 Maseki N, 26:309  
 Masuda H, 29:303  
 Mayer M, 26:299  
 McCarthy CMT, 28:87  
 McCartney AJ, 26:327  
 McCredie KB, 24:335;  
     28:213  
 Mecucci C, 25:233; 26:5;  
     26:51; 27:39; 28:113;  
     28:349; 29:171  
 Meese E, 25:285  
 Meggyessy V, 24:185  
 Mehes K, 24:185  
 Meisner LF, 29:239  
 Melamed MR, 26:261  
 Mendelow M, 24:137  
 Meriggi F, 29:253  
 Mertens F, 27:1; 28:137  
 Michael S, 26:299  
 Michalova K, 25:329

Michaux J, 27:39; 29:171  
Michaux JL, 25:233; 26:5;  
26:51  
Micic M, 28:183  
Micic S, 28:183  
Midro AT, 24:363  
Mierzewski P, 25:123  
Mikelsaar AV, 28:77  
Milasin J, 28:183  
Miller KB, 25:1; 26:105;  
26:191  
Milligan DW, 27:215  
Minamihisamatsu M,  
25:81  
Minowada J, 25:341  
Miro R, 29:91  
Misawa S, 24:257;  
25:375; 28:127  
Mise K, 29:191  
Miser J, 24:119  
Mitelman F, 24:159;  
24:315; 24:319;  
25:55; 25:161; 26:65;  
27:1; 28:137; 28:191;  
29:129  
Mitsuyasu RT, 29:245  
Mitter NS, 25:187; 26:209  
Miura O, 24:225  
Miura Y, 29:191  
Montefusco E, 27:21  
Mooibroek H, 27:361  
Moreno S, 25:355;  
28:187; 29:223;  
29:323  
Morgan R, 25:293; 26:117  
Morgan RJ, 27:215  
Morgan WF, 26:245  
Moriyama-Gonda N,  
25:317  
Morris CM, 24:271  
Morse HG, 27:51; 27:63  
Mudry de Pargament M,  
28:357  
Mugneret F, 25:373  
Muhlbauer LW, 29:165  
Muleris M, 25:7; 29:289  
Müller-Brechlin R,  
25:285; 26:369;  
28:363  
Mulvihill JJ, 24:299  
Murakami N, 24:225  
Murao S, 20:109  
Murata M, 25:81  
Murohashi I, 24:225  
Murty VVS, 26:253  
Nacheva E, 28:145  
Nahreini P, 29:65  
Nakamura H, 24:221;  
29:327  
Nakazawa S, 28:373  
Nakic M, 24:251; 25:351;  
28:353  
Nanfro JJ, 29:155  
Nanni M, 26:39; 29:129  
Narni F, 27:89  
Navarro J, 29:91  
Neff JR, 29:97  
Nelkin BD, 25:27  
Neretto G, 28:181  
Neuwirt J, 25:329  
Nieuwint AWM, 25:37  
Niitsu N, 28:373  
Nilsson P, 25:161; 28:191  
Nilsson PG, 24:315  
Nishida K, 25:375  
Nishino K, 24:221  
Nowak MJ, 28:155  
Noel P, 27:73  
Nowell PC, 24:371;  
28:173; 29:159  
Nucaro AL, 27:219  
O'Brien S, 29:319  
Ochoa-Noguera ME,  
28:293; 29:9  
Odom LF, 27:51; 27:63  
Ohde S, 28:373  
Ohsumi Y, 25:317  
Ohyashiki JH, 24:109;  
24:281; 25:1; 25:15;  
25:341; 26:105;  
26:191; 26:213;  
29:331  
Ohyashiki K, 24:109;  
24:281; 25:1; 25:15;  
25:341; 26:105;  
26:191; 26:213;  
29:331  
Olsson H, 25:55  
Oostra AB, 25:37  
Orofino MG, 27:219  
Orts MA, 26:171  
Oscier DG, 24:143  
Osinga J, 27:361  
Otaki K, 24:281  
Oyakawa Y, 24:221  
Pabinger I, 29:315  
Pacot A, 25:303; 29:9  
Paietta E, 25:227; 25:367  
Palka G, 26:5; 26:51;  
29:261  
Palmer CG, 27:241  
Panani AD, 24:63; 27:289  
Panarella C, 25:73  
Pantzar JT, 26:375  
Papa G, 26:5  
Papenhausen P, 25:227;  
25:367  
Parmentier C, 25:303  
Partington MW, 25:169  
Pasquali F, 29:253  
Pathak S, 24:7; 24:335  
Pauwels R, 29:23; 29:29  
Pedersen B, 26:227  
Pedersen-Bjergaard J,  
29:43  
Peetre C, 24:315  
Pegoraro L, 29:57  
Perissel B, 27:371  
Peterson W Jr, 27:125  
Petkovic I, 24:251;  
25:351; 28:353  
Philip P, 28:107; 29:43  
Philip T, 25:373  
Phillips JA III, 24:129;  
29:183  
Pickle LW, 24:299  
Pierotti M, 27:45  
Pigeon F, 25:259  
Pignon B, 25:259  
Pilotti S, 27:45  
Pinkerton PH, 27:375  
Pinto MR, 24:137; 24:213  
Pittman S, 26:165  
Pollak C, 26:5; 26:51  
Pollock A, 27:167  
Pollock E, 27:135  
Ponzio G, 28:181  
Postmus PE, 27:361  
Potluri VR, 24:75  
Poulsen H, 26:143  
Pressler T, 28:107  
Preisler HD, 24:281;  
25:15; 26:105; 26:213  
Prescher G, 25:183  
Prieto F, 26:171; 28:367  
Purtilo D, 27:335; 24:11  
Quinn LA, 24:17  
Raabe G, 27:177  
Rabinovitch PS, 24:191  
Raghavan D, 26:165  
Ragsdale ST, 24:87  
Raimondi SC, 24:87  
Rajic L, 24:251; 25:351;  
28:353  
Rames LJ, 28:253  
Ramos C, 24:345; 26:199;  
29:201  
Ranni NS, 25:309; 28:101  
Ranstam J, 25:55

Rao U, 26:271  
 Raptis SA, 24:63  
 Rasi V, 25:87  
 Raskind WH, 25:271  
 Ray FA, 27:273  
 Raza A, 24:181; 24:281;  
     25:15; 26:105;  
     26:213; 27:269;  
     27:311; 29:135  
 Reeves BR, 26:179;  
     26:185  
 Rege-Cambrin G, 25:233;  
     28:181  
 Reimer DL, 29:139  
 Reiss R, 27:171  
 Reiter A, 26:235  
 Repaske DR, 24:129  
 Resegotti L, 29:57  
 Reuter V, 26:253  
 Rey JA, 25:355; 26:157;  
     27:185; 28:187;  
     29:75; 29:201;  
     29:223; 29:323  
 Ricci P, 26:5; 26:51  
 Richard C, 25:185  
 Richer C, 28:229  
 Ringborg Y, 26:261  
 Riordan JR, 25:141  
 Ritter HL Jr, 24:243  
 Rivera G, 24:87  
 Rizzi R, 27:299  
 Robbins T, 26:127  
 Roberts C, 24:231; 29:119  
 Roberts CG, 27:9  
 Roberts M, 25:227  
 Robinson A, 27:51; 27:63  
 Rodgers CS, 24:45  
 Roloff B, 29:239  
 Romero P, 27:349  
 Rööser B, 24:319  
 Roozendaal KJ, 25:37  
 Rosen N, 25:227  
 Rosenberg RN, 28:163  
 Rosendorff J, 24:137  
 Rosetti A, 26:5; 26:51;  
     27:367  
 Rosman I, 24:271  
 Ross FM, 25:109  
 Rosso A, 29:57  
 Rosti G, 26:5; 26:51;  
     26:65  
 Rowe J, 26:105  
 Roza-de Jongh EJM, 24:33  
 Rubin SC, 25:21  
 Rudolph B, 26:235  
 Rümke P, 24:33  
 Russell P, 24:231  
 Russell PJ, 26:165  
 Rutland P, 27:27  
 Ruutu T, 25:87  
 Ryan DH, 26:191  
 Rydholm A, 24:319;  
     28:137  
 Sadamori N, 24:221;  
     29:327  
 Saglio G, 29:57  
 Sailer M, 27:311  
 Sait SNJ, 24:181; 26:117;  
     26:351; 27:269;  
     27:311; 29:135  
 Sakurai M, 26:309  
 Salk D, 24:191  
 Salmon R, 29:289  
 Samuel I, 29:319  
 Sandberg AA, 24:109;  
     24:181; 24:281; 25:1;  
     25:15; 25:123;  
     25:293; 25:341; 26:1;  
     26:65; 26:105;  
     26:117; 26:175;  
     26:177; 26:191;  
     26:213; 26:271;  
     26:351; 26:377;  
     27:181; 27:269; 28:1;  
     28:343; 29:135  
 Sanger WG, 25:219;  
     27:335; 29:97  
 Sarasa JL, 26:157  
 Sargent LM, 29:239  
 Sasagawa I, 24:221;  
     29:327  
 Sasaki M, 29:191  
 Sato Y, 29:191  
 Savary J, 24:355; 25:103;  
     25:371; 27:101;  
     29:311  
 Savelyeva L, 28:311  
 Sawicka A, 24:363  
 Scheerer P, 25:293  
 Schimke RN, 27:345  
 Schmeizer T, 26:5  
 Schmidt GG, 25:183  
 Schmidt MA, 27:73  
 Schorin M, 28:155  
 Schrier S, 26:117  
 Schumer J, 29:135  
 Scott DC, 28:87  
 Seabright M, 24:143  
 Seikevych IA, 26:299  
 Senn JS, 27:375  
 Sessarego M, 25:73;  
     25:265; 26:5; 26:51  
 Shabtai F, 27:171  
 Shaffer B, 29:97  
 Shapiro PE, 28:267  
 Sheer D, 26:339  
 Sheppard DM, 26:339  
 Sherrington P, 28:145  
 Shetty NJ, 24:263  
 Shirakura T, 24:359  
 Shisa H, 29:109  
 Shtalrid M, 27:349  
 Sigaux F, 28:293; 29:9  
 Siver RT, 24:295; 29:1  
 Silverstein M, 29:1  
 Simi P, 27:145  
 Simpson E, 28:287  
 Simpson JL, 25:191  
 Simpson NE, 27:327  
 Singer JW, 25:271  
 Sirinelli A, 24:151  
 Slavutsky I, 25:47;  
     25:309; 28:101;  
     28:357  
 Smadja N, 24:151  
 Smeets W, 29:23; 29:29  
 Smith A, 24:231  
 Smith S, 26:179; 26:185  
 Smyth DR, 25:131  
 Sneige N, 24:7  
 Snyderman M, 29:135  
 Solero L, 27:145  
 Soper L, 29:1  
 Soudek D, 25:169  
 Soukup SW, 29:179  
 Sozzi G, 27:45  
 Spadano A, 29:261  
 Sparkes RS, 29:245  
 Speaks SL, 27:335  
 Spector I, 24:213  
 Spielvogel A, 25:367  
 Spinner NB, 29:159  
 Sreekantaiah C, 24:263  
 Srivastava A, 29:65  
 Staal SP, 28:127  
 Stemberg J, 27:5  
 Stanley WS, 25:97  
 Stass S, 28:213  
 Stelmach T, 24:371;  
     28:173  
 Stenwig AE, 28:335  
 Sternberg A, 27:171  
 St. John DJB, 27:111  
 Stockdill G, 25:109  
 Stollmann B, 26:363  
 Strand R, 28:155  
 Strayer DR, 26:15  
 Stuppia L, 29:261  
 Su Y, 26:279  
 Sugita K, 28:373  
 Sugiyama T, 28:301;  
     29:109  
 Sullivan LD, 29:103

Surti U, 29:271  
Swansbury GJ, 28:375  
Szücs S, 26:369; 28:363  
Szüle E, 24:185

Tagawa M, 24:221; 29:327  
Takagi T, 25:81  
Takahashi E, 25:81  
Takahashi R, 28:301; 29:109  
Takai S, 24:225  
Takeda T, 24:359  
Takeuchi J, 24:109  
Takino T, 24:257; 25:375  
Talpaz M, 27:349  
Tanaka K, 25:27  
Taniwaki M, 24:257; 25:375  
Tarantino E, 27:145  
Tassinari A, 26:65  
Tattersall MHN, 24:231; 27:9; 29:119  
Templado C, 29:91  
Testa JR, 25:27; 28:127  
Testoni N, 26:5; 26:51; 26:65; 28:113  
Teyssier J, 25:179; 25:259  
Thay TY, 24:177  
Thiele CJ, 24:119  
Thomas S, 24:295  
Thurber WA, 24:11  
Tiefenbach A, 24:251; 25:351; 28:353  
Toledo C, 26:199  
Tommerup N, 27:225  
Tomonaga M, 24:221  
Tonomura A, 24:225  
Törzsök F, 24:185  
Toyama K, 29:331  
Traganos F, 26:261  
Travade P, 27:371  
Trent JM, 25:141; 26:187; 28:3  
Tricot G, 25:233; 27:39; 27:241  
Trivedi AH, 27:33  
Trujillo J, 24:7; 27:349  
Trujillo JM, 28:213  
Tsai S, 24:299  
Tucker J, 25:175; 28:287  
Tully SM, 28:93

Tura A, 26:65  
Tura S, 26:3; 26:5; 26:51  
Turc-Carel C, 25:373; 26:177; 26:377  
Turchini MF, 27:371  
Tygstrup I, 27:107  
Tytgot H, 28:113

Uehara M, 25:253  
Usui T, 25:317

Valcarcel E, 24:345; 27:185  
Valensi F, 28:293; 29:9  
Valenti S, 26:5; 26:51  
Van Den Berghe H, 25:233; 26:5; 26:51; 26:175; 27:39; 28:49; 28:113; 28:349; 29:171  
van der Kamp AWM, 24:33  
van Haften-Day C, 24:231  
van Hemel JO, 24:33  
Van Hoof A, 28:349  
Van Hove W, 25:233  
Vannais D, 27:51; 27:63  
Van Orshoven A, 27:39  
Van Velzen-Tillemans JTM, 24:33  
Vecchione D, 25:303; 29:9  
Vejerslev LO, 26:143; 27:225  
Verma RS, 24:295; 24:367  
Vermaelen K, 27:39  
Verp MS, 25:191  
Vielh P, 29:289  
Vogelstein B, 29:165  
Volk C, 25:373  
Vonderheid EC, 27:89; 29:159  
Vlachos JD, 24:63  
Vyas RC, 27:33

Walen KH, 25:149  
Walling P, 27:277  
Wang N, 28:155  
Wang R, 29:81  
Wang-Wuu S, 26:279; 29:179

Warburton D, 28:267  
Ward B, 26:339  
Warmoth LA, 28:163  
Warrior RP, 28:155  
Wass J, 26:165  
Wechsler A, 25:309  
Weiden PL, 24:243  
Weisenburger D, 27:335  
Weiskopf RW, 26:209  
Welborn JL, 28:277  
Wells IC, 25:247  
Westin EH, 27:251  
Whang-Peng J, 24:119; 29:155  
Wheeler K, 28:377  
Whelan RDH, 26:339  
White BN, 27:327; 29:139  
Whitehead RH, 27:111; 27:357  
Whitmore WF, 26:253  
Wiernik PH, 25:227; 25:367  
Willard HF, 25:141  
Willen H, 24:319; 28:137  
Williams DL, 24:87  
Williams J, 27:215  
Winberg JO, 24:327  
Witkowski CM, 26:187  
Wojtukiewicz M, 24:363  
Wong AJ, 29:165  
Wong L, 26:179; 26:185  
Wuu K, 26:279

Yamada Y, 24:221  
Yamamoto K, 28:373; 29:175  
Yang C, 26:379  
Yang JPS, 24:11  
Yao E, 24:221; 29:327  
Yokota J, 29:303  
Yoshida MA, 24:281  
Young BD, 28:287

Zaccaria A, 26:3; 26:5; 26:51; 26:65  
Zafrani B, 29:289  
Zandecki M, 27:101; 29:311  
Zander A, 24:7  
Zang KD, 25:285  
Zubizarreta A, 25:185



---

## Subject Index to Volumes 24-29

---

Acquired idiopathic sideroblastic anemia (AISA)  
i(7q), 25:49

Acute leukemia  
in vitro differentiation, 28:327  
T-cell receptor, 28:327  
with t(4;17), T-lymphoid and myeloid surface antigens, 28:327

Acute lymphoblastic leukemia (ALL)  
bone marrow transplantation, 26:51  
cell line, 25:379  
chromosome studies, 26:51, 59  
constitutional chromosome changes, 24:345  
constitutional r(21), 27:219  
DNA measurements in adult, 28:213  
in Down syndrome, 28:155  
NALM-cell lines, 25:341  
NOR in marrow cells, 25:65  
pre-B with t(1;19), 25:379  
t(1;19) in pre-B, 25:379  
t(8;12;14) in Burkitt-type ALL, 28:145  
telomeric association, 24:87  
tetraploidy, 29:129  
1q trisomy, 24:87, 251  
1q+ in ALL, 24:251  
5q- and fms gene, 25:341  
+ 9 constitutional in, 24:345

Acute lymphocytic leukemia; see Acute lymphoblastic leukemia (ALL)

Acute monoblastic leukemia (AMoL)  
Auer rods and cytogenetics, 28:191  
chromosome changes with inv(16), 26:309  
DNA measurements in adult, 28:201  
inv(16) in M5b, 26:309  
t(8;16) in M5a, 24:213  
11q13 in, 26:351

Acute myeloblastic leukemia (AML); see also Acute nonlymphocytic leukemia  
Auer rods and chromosomes, 28:191  
chromosome changes in, 25:329  
constitutional t(3;6), 25:87  
DNA measurements in adult, 28:213

i(7q), 24:49  
i(11q), 24:49  
i(17q) in M2, 24:315, 25:49  
M2 with 9q-, 24:177  
Sweet's syndrome with t(3;5), 28:87  
t(6;9) in, 26:363  
t(7;11) and c-Ha-ras-1, 29:199  
with t(8;16), DIC and bone marrow necrosis, 24:243  
XYY in M2, 24:363  
5q- in, 26:199

Acute myeloid leukemia; see Acute nonlymphocytic leukemia

Acute myelomonocytic leukemia (AMMoL)  
Auer rods and cytogenetics, 28:191  
chromosome changes in, 25:329  
DNA measurements in adult, 28:201  
double minutes and normal karyotype, 25:1  
fragile site on #16, 25:81  
i(17q), 25:49  
in patient with familial t(6;16), 29:159  
inv(16) and other changes, 26:309  
inv(16) in eosinophils, 29:327  
inv(16) in XY/XYY male, 29:331  
inv(16) (p13q22), fra(16)(q22), 25:81  
M4 with t(1;11), 24:181  
t(7;11), 26:191  
t(8;16) in, 27:101  
11p changes, 28:287  
11q13 in, 26:351

Acute nonlymphocytic leukemia (ANLL)  
AML with 9q-, 24:177  
AMMoL with t(1;11), 24:181  
AMoL with t(8;16), 24:213  
Auer rods and cytogenetics, 28:191  
bone marrow transplantation, 26:51  
c-mos studies, 24:137  
cell kinetics, 28:357  
changes in Chinese patients, 26:379  
chromosome changes in, 25:329; 26:51, 28:293; 29:9  
chromosome changes in secondary ANLL, 29:43

(ANLL) con't  
 constitutional chromosome disorder, 24:345  
 DNA measurements in adult, 28:201  
 double minute chromosome, 25:1  
 Down syndrome, 28:155  
 i(17q) in M2, 24:315  
 inv(12) constitutional in, 24:345  
 inv(16) in t-ANLL, 27:167  
 NOR in marrow cells, 25:65  
 prognostic significance of cytogenetic findings, 28:293  
 rheumatoid arthritis, 25:161  
 ring (21) constitutional in, 24:345  
 secondary, 26:65; 29:43  
 t(1;7), a correction, 25:187  
 t(3;5), 28:261  
 t(6;9) in, 26:363  
 t(8;16) in, 27:101  
 t(8;16) in AML with DIC and marrow necrosis, 24:243  
 t(8;21) in AML, 24:137  
 t-ANLL (therapy related), 27:167  
 therapy related (t-ANLL), 27:167  
 translocations and deletions involving 21q in secondary ANLL, 29:43  
 trisomy 21 (+ 21) in, 24:345  
 + 4, 26:117, 171, 175  
 5q- in, 26:199  
 11p changes, 28:287  
 11q13 in, 26:351  
 21q breakpoint in secondary ANLL, 29:43

Acute promyelocytic leukemia (APL)  
 Auer rods and cytogenetics, 28:191  
 DNA measurements in adult, 28:201  
 in CML, 28:349  
 t(15;17) and t(2;17;15) in a case, 28:107  
 t(X;15) in, 29:65  
 variant t(15;17), 28:349

Adenoma(s)  
 marker similar to one in endometrial cancer, 27:177  
 pleomorphic, 28:237  
 pleomorphic with t(3;8;8), 27:177

Adipose tissue tumors  
 rings in lipogenic tumors, 24:319

Adrenocortical carcinoma, 26:271; 28:343  
 t(4;11) in, 28:343

AIDS  
 + 12 in Burkitt-like lymphoma, 29:245

Amplification  
 c-myc in human leukemia sublines, 28:127  
 in gliomas, 29:165  
 in HSR, 29:139

Anemia  
 aplastic, 24:345  
 constitutional chromosome changes, 24:345  
 Fanconi, 25:37  
 refractory and double minutes, 28:367  
 refractory with - 2, 28:367  
 refractory with 5q-, 24:159  
 refractory with excess of blasts, 25:175  
 t(6;9), 29:135  
 5q- in refractory anemia, 28:375  
 + 14 in RAEB, 29:325

Animal cells  
 Abelson virus induced, 28:119  
 Chinese hamster, 27:273  
 karyotypes in Chinese hamster cells, 27:273  
 mouse leukemia cells, 29:109  
 mouse lymphoma, 28:119  
 neoplastic evolution, 27:273

Astrocytoma  
 chromosomal patterns, 29:201

Ataxia telangiectasia  
 cancer proneness, 26:85  
 CLL in, 26:217  
 cytogenetics, 26:85, 217  
 T-cell CLL, 26:217

Auer rods  
 AML and, 28:191  
 ANLL and, 28:191

B-cells(s)  
 CLL, 24:145; 25:109; 26:75  
 in PHA-stimulated lymphocytes, 29:151  
 lymphoma, 24:271  
 mitogens, 24:109, 25:109  
 molecular studies, 27:251  
 polyclonal activators, 24:109  
 pre-B ALL, 26:379  
 TPA as mitogen, 26:109  
 bcr (Breakpoint cluster region)  
 in CML, 26:105; 27:349; 29:1, 57  
 in CML cell line K562, 26:105  
 in CML cell lines, 25:271; 26:105; 27:349  
 in masked Ph, 25:15, 105  
 in variant Ph, 26:105  
 rearrangements in CML, 25:15, 105; 29:1, 57  
 studies in blastic phase, 29:57  
 value of analysis in CML, 29:1

Bladder  
 chromosome changes, 29:29  
 familial cancer, 27:161  
 method for analysis of biopsies, 29:103  
 method for cytogenetic analysis, 29:23, 103  
 ring chromosomes, 28:183  
 tumors, embryonal origin, 24:189

**Blast crisis**  
  APL with variant t(15;17) in, 28:349  
  bcr studies, 29:57  
  double minutes in CML, 25:253  
  in thrombocythemia, 25:227  
  karyotypes in, 26:39  
  lymphoid in Ph-positive  
    thrombocythemia, 25:227  
  masked Ph in, 26:42  
  morphology of cells, 26:42  
  Ph and 9q+ duplication, 29:57  
  promyelocytic with t(15;17), 29:311  
  rings in CML, 25:253  
  surface markers, 26:25

**Bloom syndrome**  
  cancer proneness, 26:85  
  cell lines, 26:287  
  cytogenetics, 26:85  
  DMS in cell line, 26:287  
  fibroblast cultures, 26:287  
  oncogene expression, 26:287

**Bone marrow**  
  BrdU and cell synchronization, 28:229  
  changes in ANLL, 25:329  
  changes in CLL, 25:109  
  changes in PV, 25:233  
  disease with t(11;22) and other changes, 28:277  
  methodology, 28:229  
  necrosis with DIC and t(8;16) in AML, 24:243  
  NOR in cells, 25:65  
  transplantation in ALL, 26:51  
  transplantation in ANLL, 26:51  
  transplantation in CML, 26:5

**Brain tumors**  
  astrocytoma, 29:201  
  C-bands in patients, 27:185  
  cell lines, 24:163  
  clinical significance of chromosome changes, 26:127  
  cytogenetics of, 24:163; 26:127  
  gene amplification in gliomas, 29:165  
  glioblastoma cell line and oncogenes, 25:285  
  gliomas, 24:163; 29:223  
  meningioma, 26:127  
  metastatic lung tumors with 3p-, 25:355  
  + 7 in gliomas, 29:323

**Breakpoints**  
  in rectal cancer, 25:7  
  3p21 and 3q25 in CML, 27:371  
  13q in retinoblastoma, 27:27

**Breast cancer**  
  chromosome breakage, 24:52  
  chromosome changes in 24:45; 27:289  
  cytogenetics of, 24:52

  double minutes in, 24:52  
  HSR in, 24:52  
  karyotypes in, 24:52; 27:289  
  oncogenes in glioblastoma cell line, 25:285  
  PCC, 24:52  
  rings, 24:52  
  triploid/tetraploid tumors, 24:45  
  #8 and #13 in, 24:45

**Brunner tumor**  
  in gonadal dysgenesis, 25:191

**Burkitt**  
  translocation t(2;8), 24:225  
  type ALL with t(8;12;14), 28:145

**Cancer cytogenetics**  
  background, 28:5; 29:198  
  historical, 28:5  
  hypotheses, 28:5  
  origin, 29:187

**Carcinoid**  
  cell line, 24:17  
  COLO 320 cell line, 24:17  
  double minutes, 24:17  
  non-c-myc DNA, 24:17  
  of colon, 24:17

**C-band(s)**  
  heteromorphism, 27:33  
  in breast cancer, 28:77  
  in cancer families, 27:261  
  in CML cases, 27:33  
  in multiple myeloma, 28:101  
  in nervous system tumors, 27:185  
  in nonpolyposis colon cancer syndrome, 27:111  
  in ovarian cancer, 28:77  
  mosaicism of chromosome 1 in cancer families, 27:261

**Cell kinetics**  
  in hematologic disorders, 28:357

**Cell line(s)**  
  ALL, 25:379  
  amniocyte, 25:149  
  Bloom syndrome fibroblasts, 26:287  
  Chinese hamster, 27:273  
  CML, 24:335; 25:271  
  COLO 320, 24:17  
  colon cancer, 27:111, 125, 357  
  colon carcinoid, 24:17  
  DMBA-induced, 28:301  
  dysplastic nevus syndrome, 24:33  
  erythroleukemia (D5A1) with chromosome marker, 28:301  
  gliomas, 24:163  
  HeLa-76, 28:311  
  hepatoma, 26:279  
  HL-60 cells, 27:311  
  human leukemia (HL-60), 28:127

Cell line(s) con't  
 human T-cell leukemia, 29:119  
 K562 (CML), 26:105  
 lung adenocarcinoma, 26:317  
 mouse (LM, A9, Rag), 24:95  
 mouse melanoma, 29:81  
 near-haploid and Ph-positive, 24:335  
 neuroectodermal tumor, 24:75  
 osteosarcoma with #13 anomaly, 24:327  
 ovarian cancer, 24:231; 26:339; 28:201  
 plasma cell, 27:135  
 primitive neuroectodermal tumor, 24:75  
 prostate cancer, 26:165  
 rRNA amplified in T-cell line, 28:119  
 thyroid cancer, 27:27  
 transformed by SV40, 25:149  
 WiDr and HT-29 colon cancer, 27:125

Cervical cancer  
 PCC in, 24:263

Chromosomal location  
 c-met, 26:187  
 cystic fibrosis gene, 26:187  
 mdrl gene, 26:187  
 P-glycoprotein locus on 7q36, 25:141; 26:187  
 7q36 locus for P-glycoprotein, 25:141

Chromosome  
 #1 in ALL, 24:87  
 #1 in endometrial cancer, 25:21  
 #1 in Ewing sarcoma, 25:97  
 #1 in gastric cancer, 24:63  
 #1 in neuroectodermal tumor cell line, 24:75  
 #1 in ovarian cancer cell lines, 24:231  
 #1 in secondary lymphoma, 24:7  
 #1, #3 and #6 in ovarian cancer cell line, 26:339  
 #2 in MDS, 26:227  
 #3 in hairy cell leukemia, 24:109  
 #3 in lung cancer, 25:355; 27:361  
 #3 in lymphoma, 25:55  
 #3 in renal cancer, 26:253  
 #4 in ANLL, 26:117, 171, 175  
 #5 in preleukemia and leukemia, 26:199  
 #5 in PV, 25:233  
 #6 in ovarian cancer cell lines, 24:231  
 #7 in gastric cancer, 24:63  
 #7 in gliomas, 29:323  
 #7 in hematologic disorders, 25:47  
 #7 in lymphoma, 25:55  
 #7 in MPD, 26:209  
 #7 in PV, 25:233  
 #7, #1 and #9 in myeloproliferative disorders, 24:151  
 #8 in ANLL, 27:269  
 #8 in breast cancer, 24:45  
 #8 in gastric cancer, 24:63  
 #8 in MDS, 26:227  
 #8 in mixed salivary gland tumors, 24:205  
 #9 in gastric cancer, 24:63  
 #9 in MDS, 26:227  
 #10 in endometrial cancer, 25:21  
 #10 in hairy cell leukemia, 24:109  
 #11 and iron stores in MDS, 24:39  
 #11 in ANLL, 26:351; 28:287  
 #11 in hematologic disorders, 25:47; 28:287  
 #11 in secondary lymphoma, 24:7  
 #12 in CLL, 25:109; 26:75; 28:93  
 #12 in lymphoma, 25:55; 29:245  
 #12 in ovarian tumor, 26:355  
 #13 in breast cancer, 24:45  
 #13 in hematologic disorders, 24:143  
 #13 in osteosarcoma cell line, 24:327  
 #13 in PV, 25:233  
 #14 in AT with T-CLL, 26:217  
 #14 in RAEB, 29:315  
 #16 in AMMol (M4), 24:251  
 #17 and pseudo-Pelger-Huet anomaly, 25:265  
 #17 in CML, 25:265  
 #17 in hairy cell leukemia, 24:109  
 #17 in hematologic disorders, 25:47  
 #17 in MDS, 26:227  
 #20 in MEN-II, 24:129; 27:327; 28:253  
 #20 in PV, 25:233  
 #21 in hematologic disorders, 25:47  
 #21 in secondary lymphoma, 24:7  
 #22 in meningioma, 26:127; 27:145

Chromosome breakage; see also  
 Chromosome instability disorders  
 in amniocyte cell lines, 25:149  
 in breast cancer, 24:52  
 in Fanconi anemia, 25:37

Chromosome changes  
 constitutional in hematopoietic disorders, 24:345  
 deletions in MDS, 26:227  
 dup(11q) partial in secondary lymphoma, 24:7  
 dysplastic nevus syndrome (DNS), 24:33  
 i(17q) in AML, 24:315  
 in a transplantable melanoma, 25:123  
 in adrenal cancer, 26:271  
 in ALL, 24:87; 26:59  
 in AML, 25:329; 28:191  
 in AMMol (M4), 24:257  
 In ANLL, 25:329; 26:351, 269; 28:191, 293  
 in astrocytomas, 29:201  
 in bladder cancer, 29:29  
 in blast crisis of CML, 26:39

in breast cancer, 24:45; 27:289  
in CLL, 24:143; 25:109; 26:75; 28:93  
in CML, 24:143, 281; 25:75, 267, 329; 26:25, 39  
in colorectal tumors, 29:289  
in gastric cancer, 24:63  
in gliomas, 24:163; 29:223  
in hairy cell leukemia, 24:109  
in HeLa cell line, 28:311  
in hematologic disorders, 24:143  
in lymphocytes of thyroid cancer patients, 25:303  
in lymphoma, 24:271; 25:223; 27:335  
in MDS, 24:143; 25:329; 26:227; 27:39  
in megakaryoblastic leukemia, 25:259  
in MEN-II, 24:129; 27:327; 28:253  
in meningioma, 26:127; 27:145  
in mesothelioma, 29:75  
in MPD, 24:143, 151; 25:329  
in neuroblastoma, 26:235  
in neuroectodermal tumor cell line, 24:75  
in neurofibroma, 26:157  
in osteosarcoma cell line, 24:327  
in ovarian cancer cell lines, 24:231; 26:339  
in ovarian tumors, 26:327, 355  
in pancreatic cancer, 29:253  
in peripheral neuroepithelioma, 24:119  
in PNH, 25:259  
in prostate cancer, 26:165  
in renal cancer, 26:253  
in secondary conditions, 26:65  
in Sézary syndrome, 27:79  
in solid tumors, 26:177  
in T-cell (cutaneous) lymphoma, 28:267  
in T-CLL of AT, 26:217  
in Waldenström's macroglobulinemia, 29:261  
inv(16) in M4, 24:257; 25:81; 26:309  
iso(11q) in Ewing sarcoma, 25:97  
isochromosomes in hematologic disorders, 25:47  
multiple myeloma, 25:309  
polycythemia vera, 25:233  
prognosis in lymphoma, 25:55  
thyroid cancer cell line, 25:27  
trisomy 1q in essential thrombocythemia, 25:185  
with inv(16), 26:309  
1p+ in lymphoma, 25:55  
1q+ and +10 in endometrial cancer, 25:21  
1q+ or +1 in neuroectodermal tumor, 24:75  
1q21 abnormality in secondary lymphoma, 24:7  
3p in renal cell carcinoma, 25:179  
5q- in preleukemia and leukemia, 26:199  
5q- in refractory anemia, 24:159; 26:199  
6q- in lymphoma, 25:55  
+8, +9, 13q-, 20q- in PV, 25:233  
8q+ and i(8q) in gastric cancer, 24:63  
9q- deletion in AML, 24:177  
+9, i(9q) or 9p+ in gastric cancer, 24:63  
12p- in dysplastic nevus syndrome (DNS), 24:39  
-13 in neuroectodermal tumor, 24:75  
13q14 in hematologic diseases, 24:143  
14q+ in lymphoma, 24:271; 25:55  
17p+ and t(5;20) in MDS, 24:371  
20p12 in MEN-II, 24:129; 27:327  
-21 in possible secondary lymphoma, 24:7  
Chromosome instability disorders  
dysplastic nevus syndrome, 24:299  
in family with gastric cancer, 27:299  
Chronic granulocytic leukemia; see Chronic myelocytic leukemia  
Chronic lymphocytic leukemia (CLL)  
chromosome changes in, 24:145; 25:109; 26:75; 28:93  
clinical correlations, 26:75  
cytochalasin B and EBV as mitogens, 28:93  
oncogenes, 25:119  
origin of +12, 28:185  
T-cell in AT, 26:217  
translocations, 25:109  
+12, 25:109; 26:75; 28:93, 185  
13q14 in, 24:143  
Chronic myelocytic leukemia (CML)  
APL with variant t(15;17) in, 28:349  
atypical t(9;12;22), 25:183  
bcr in cell lines, 25:271  
bcr in masked Ph, 25:15  
bcr rearrangement in masked Ph, 26:105; 27:21  
bcr studies, 26:105; 27:21; 29:57  
bone marrow transplantation, 26:5  
C-bands, 25:131  
C-bands in lymphocytes, 27:33  
c-myc in, 27:349  
cell colonies, 24:1  
cell line, Ph-positive, 24:335; 25:271  
cell surface markers, 26:25  
chromosome changes in, 24:145, 281; 25:73, 267, 329; 26:5, 25  
chromosome 17 and pseudo-Pelger-Huet anomaly, 25:265  
complex Ph chromosomes, 24:281, 359

(CML) con't  
 double minutes in blastic phase, 25:253  
 duplication of Ph and 9q+, 29:57  
 erythrocytosis in, 24:359  
 flow cytometry of cells, 24:337  
 karyotype evolution, 25:73  
 karyotypes, 25:75, 267  
 markers in patient management, 26:25  
 masked Ph, 24:281; 25:15, 165; 26:42; 27:21  
 molecular studies in, 27:349  
 myelofibrosis with t(1;3), 25:361  
 near-haploid, 24:335  
 oncogene *abl* in CML, 26:15; 27:349  
 oncogene activity, 26:15  
 oncogene *sis* in CML, 26:15  
 PDGF in, 26:15  
 Pelger-Huet anomaly, 25:265  
 Ph chromosome, 24:281  
 Ph-positive CML with myelofibrosis and t(1;3), 25:361  
 promyelocytic crisis with t(15;17), 29:311  
 pseudo-Pelger-Huet anomaly and i(17q), 25:265  
 retroviral activity, 26:15  
 rings in blastic phase, 25:253  
 secondary and Ph+, 28:173  
 t(7;11) and c-Ha-ras-1, 29:191  
 t(7;11) in atypical, 26:191  
 t(8;21), 25:103  
 t(12;22), 25:183  
 t(20;22), 25:183  
 translocations other than Ph, 25:73, 267  
 value of *bcr* analysis, 29:1  
 with four Ph, 28:179  
 Y polymorphism, 24:295  
 3p21 and 3q25 breaks, 27:371  
 -7 in secondary CML, 28:173  
 +8, i(17q), +Ph, +19 in, 25:73  
 13q14 in, 24:143  
 Chronic myelomonocytic leukemia (CMMoL)  
 t(1;7), 24:355  
 Cloning  
 double minutes, 24:17  
 non-c-myc DNA, 24:17  
 Colon  
 adenocarcinoma cell line: WiDr, 27:125  
 C-bands in patients, 27:111  
 cancer in black family, 24:1  
 carcinoid cell line, 24:17  
 chromosomal changes, 29:289  
 colorectal tumors, 29:289  
 extracolonic manifestations of polyposis, 27:319  
 inv(16) in, 27:171  
 nonpolyposis cancer syndrome, 27:111  
 SCE in nonpolyposis syndrome, 27:111  
 sigmoid cancer with inv(16), 27:171  
 t(1;13) as only change, 27:357  
 Colonies  
 fluoroxuryidine synchronization, 24:1  
 hematopoietic, 24:1  
 Ph-positive cells, 24:1  
 synchronization, 24:1  
 Constitutional chromosome changes  
 in hematologic disorders, 24:345  
 r(21) in ALL, 27:219  
 ring (22) with neurofibromatosis, 25:169  
 risk of hematologic malignancy, 24:375  
 sex chromosome abnormalities, 25:191  
 t(3;6) in family with hematologic disease, 25:87  
 t(6;16) and M4, 29:159  
 t(13;14) carrier with testicular tumor, 25:299  
 Cryptorchidism  
 testicular tumors, 25:191  
 Cyclophosphamide  
 effects on chromosomes of lymphocytes, 29:239  
 Cystic fibrosis  
 c-met gene, 26:187  
 molecular studies, 26:187  
 P-glycoprotein gene, 26:187  
 Cytogenetics; see also Karyotype  
 chromosome changes  
 breast cancer, 24:45; 27:289  
 dysplastic nevus syndrome (DNS), 24:33  
 gastric cancer, 24:63  
 in adrenal cancer, 26:271  
 in AML, 25:329  
 in ANLL, 25:329; 29:9  
 in astrocytomas, 29:201  
 in bladder cancer, 29:29  
 in blastic phase of CML, 25:39  
 in CML, 24:281; 25:75, 267, 329; 26:25, 39  
 in colorectal tumors, 29:289  
 in gliomas, 29:223  
 in hairy cell leukemia, 24:109  
 in HeLa cell line, 28:301  
 in lymphoma, 24:271; 25:223; 27:335  
 in MDS, 25:329; 27:39  
 in megakaryoblastic leukemia, 25:259  
 in meningioma, 26:127; 27:145  
 in mesothelioma, 29:81  
 in MPD, 24:151; 25:329  
 in multiple myeloma, 25:309  
 in neuroblastoma, 26:235  
 in neurofibroma, 26:157  
 in ovarian tumors, 26:327, 355  
 in peripheral neuroepithelioma, 24:119  
 in PNH, 25:259  
 in prostate cancer, 26:165

in renal cancer, 26:253  
in secondary ANLL, 29:43  
in secondary lymphoma, 24:7  
in Sézary syndrome, 27:79  
in Waldenström's macroglobulinemia, 29:261  
neuroectodermal tumor cell line, 24:75  
of ALL, 24:87  
of CLL, 25:109; 26:75; 28:93  
of gliomas, 24:163  
of hematologic malignancies, 24:143  
of lymphocyte cultures and effects of cyclophosphamide, 29:239  
of ovarian cancer cell lines, 24:231; 26:339  
of solid tumors, 26:177  
of somatic cell hybrids, 24:95  
polycythemia vera, 25:233  
prognosis in lymphoma, 25:55  
T-cell (cutaneous) lymphoma, 28:267  
thyroid cancer cell line, 25:37  
with inv(16), 26:309

**Cytometry**  
cell flow measurements, 24:191  
genomic size of normal and neoplastic cells, 24:191  
in CML, 24:337

**Deletion(s)**  
del(X) in dysplastic nevus syndrome (DNS), 24:39  
in MDS, 26:227  
in PV, 25:233  
interstitial of 9q in AML, 24:177  
#1 in ovarian cancer cell lines, 24:231  
3p- in lung cancer, 27:45  
3p- in renal cancer, 25:179; 26:253, 369  
5q- in leukemia, 26:199  
11p in ANLL, 28:287  
11q-, iron stores and MDS, 27:39  
13q in retinoblastoma, 27:27  
13q14 in MDS, 28:181  
21q in secondary ANLL, 29:43

**Disseminated intravascular coagulation (DIC)**  
with bone marrow necrosis, DIC and t(8;16) in AML, 24:243

**DNA**  
analysis in MEN-II, 24:129  
c-mos localization, 24:137  
cDNA and P-glycoprotein, 25:141  
in glioblastoma cell line, 25:285  
markers in multiple endocrine neoplasia, 27:327  
measurements in adult acute leukemia, 28:213  
measurements in normal and neoplastoid cells, 24:191

non-c-myc in carcinoid, 24:17  
p446 probe, 24:17  
polymorphic probes, 28:335  
rDNA in mouse leukemia line, 29:109  
reiterated sequences in cancer, 28:163  
studies in CML cell lines, 25:271

**Double minute chromosomes**  
blastic phase of CML, 25:253  
CML in blastic phase, 25:253  
in a gastric cancer, 24:64  
in AMMoL, 25:1  
in astrocytomas, 29:201  
in Bloom syndrome fibroblasts, 26:287  
in breast cancer, 24:52  
in c-myc amplification, 28:127  
in colon carcinoid cell line, 24:17  
in mouse mammary cancer line, 25:317  
in ovarian cancer cell line, 24:231  
in refractory anemia, 28:367  
in Shionogi cell line, 25:317  
non-c-myc DNA, 24:17

**Down syndrome**  
acute leukemia in, 24:345; 28:55, 155  
ALL, 28:155  
ANLL, 28:155  
chromosome changes in leukemia, 28:155  
epidemiology, genetics, cytogenetics and leukemogenesis, 28:55  
hematologic disorders, 24:345; 28:155  
transient megakaryoblastic proliferation, 28:373

**Dysgerminoma**  
chromosome changes in, 26:327  
i(12p) in, 26:327, 355  
in gonadal dysgenesis, 25:191

**Dysplastic nevus syndrome (DNS)**  
and malignant melanoma, 24:299  
chromosome changes in, 24:33, 299  
cytogenetics, 24:299  
hyperdiploidy in, 24:33  
lymphocytes, 24:33  
SCE in cells, 24:33

**Endometrial cancer**  
karyotype in well-differentiated adenocarcinoma, 25:21

**Eosinophils**  
in M4 with inv(16), 29:327  
inv(16) in, 29:327  
MPD with chromosome 7 abnormality, 26:209

**Erythroleukemia, acute**  
Auer rods and cytogenetics, 28:191  
c-Ha-ras expression in cell lines, 28:301  
cell line (D5A1), 28:301  
DNA measurements in adult, 28:201

**Esthesioneuroblastoma**  
t(11;22), 29:155

**Ewing sarcoma**  
isochromosome 11, 25:97

**Familial**  
bladder cancer, 27:161  
cancer, 24:11  
colon cancer, 24:11  
dysplastic nevus syndrome (DNS), 24:33  
hematologic malignancies and  
constitutional t(3;6), 25:87  
in black family, 24:11  
polyposis coli, 27:319; 28:245  
polyposis coli and neurofibromatosis,  
28:245  
t(6;16) and M4, 29:159  
XY gonadal dysgenesis and tumors,  
25:191

**Fanconi anemia**  
cancer proneness, 25:85  
chromosome analysis, 25:37; 26:85  
chromosome breakage, 25:37; 26:85  
cytogenetic toxicity of paraquat and  
streptonigrin, 25:37

**Fibroblasts**  
chromosome changes in, 24:33  
dysplastic nevus syndrome (DNS), 24:33  
hyperdiploidy and cancer, 26:261  
in nasopharyngeal cancer, 26:261  
SCE in, 24:33

**Fluorodeoxyuridine**  
hematopoietic colonies, 24:1  
synchronization, 24:1

**Fragile sites**  
fra(16)(q22) in ANLL, 25:81  
heritable and cancer, 25:81, 26:95  
in nonpolyposis colon cancer syndrome,  
27:111  
lymphocytes, 26:95  
malignancy and, 26:95  
noninvolvement of 10q24.2 in rectal  
cancer, 25:7

**Gastric cancer**  
chromosome instability in family with,  
27:299  
cytogenetic findings in, 24:63  
#7 in, 24:63  
8q+ and i(8q), 24:63  
#9 in, 24:63  
+ 9, i(9q) or 9p+ in, 24:63

**Gene(s)**  
amplification in gliomas, 29:165  
amplification in tissue culture, 29:119  
amplified in HSR, 26:245  
cystic fibrosis, 26:187  
locus for P-glycoprotein, 25:141  
mdrl-gene, 26:187  
N-myc in neuroblastoma, 26:235  
P-glycoprotein, 26:187  
probes, 27:91

**Glioblastoma**  
cell line, 25:285  
oncogene expression in cell line, 25:285

**Glioma**; see also **Brain tumors**  
astrocytoma, 29:201  
cell lines, 24:163; 25:285  
chromosome changes, 24:163; 25:285;  
29:165, 223  
gene amplification, 29:165  
+ 7 in, 29:323

**Gonadal dysgenesis**  
Brunner tumor, 25:191  
dysgerminoma, 25:191  
gonadoblastoma, 25:191  
hilus-cell adenoma, 25:191  
neoplasia in, 25:191  
review, 25:191  
tumors in, 25:191

**Gonadoblastoma**  
in gonadal dysgenesis, 25:191  
Turner syndrome, 25:191

**Hairy cell leukemia (HCL)**  
cytogenetic studies in, 24:109  
#3, #10 and #17 in, 24:109

**Hematopoietic (Hematologic) disorders**  
13q14 in malignancies, 24:143  
colonies, 24:1  
constitutional chromosome changes,  
24:345  
isochromosomes, 25:47  
myeloproliferative diseases, 24:151  
secondary disorders due to therapy,  
26:65

**Hepatoma**  
cell line, 26:279  
karyotype of cell line, 26:279

**Hereditary**  
ovarian cancer, 25:247

**Hermaphroditism**  
neoplasia in, 25:191

**Heterochromatin**  
C-bands in cancer families, 27:261  
C-bands in CML, 27:33  
C-bands in ovarian and breast cancer,  
28:77  
constitutive of Y in CML, 24:295  
in hydatidiform moles, 26:143  
in multiple myeloma, 28:101  
of Y in boys with various tumors,  
25:351

**Heteromorphism**; see also  
Heterochromatin  
C-bands in cancer families, 27:261

C-bands in CML, 27:33  
C-bands in multiple myeloma, 28:101  
C-bands in nervous system tumors, 27:185  
C-bands in nonpolyposis colon cancer syndrome, 27:111  
C-bands in ovarian and breast cancer, 28:77  
Heterozygosity  
  chromosome 13 in polyposis, 28:325  
  loss in osteosarcoma, 28:335  
  loss in polyposis tumor (duodenal), 28:335  
Hilus-cell adenoma  
  in gonadal dysgenesis, 25:191  
Histiocytoma  
  chromosome findings, 29:97  
  malignant (fibrous), 29:97  
  + 7 in, 29:97  
Homogeneously staining regions (HSR)  
  amplification, 29:139  
  in breast cancer, 24:52  
  in cell line, 24:17  
  in colon carcinoid, 24:17  
  SCE in, 26:245  
  unequal crossing-over and, 29:139  
Hybrids  
  cell lines (LM, A9, Rag), 24:95  
  mouse cells, 24:95  
  somatic cell, 24:95  
Hydatidiform mole  
  chromosome heteromorphism, 26:143  
  complete, 29:271  
  cytogenetics of trophoblasts, 29:271  
  DNA-aneuploidy, 27:225  
  genetic markers, 26:143  
  heterozygous 46,XX, 26:143  
  heterozygous 46, XY, 26:143  
  homozygous 46, XX, 26:143  
Hyperdiploidy  
  in dysplastic nevus syndrome (DNS), 24:33  
  in fibroblasts of cancer patients, 26:261  
  in nasopharyngeal cancer, 26:261  
Immunoglobulin(s)  
  atypical lymphoid hyperplasia, 27:251  
Insertions  
  ins(2;13) in CLL, 24:143  
  ins(4;11) in PV, 24:238  
  ins(6;11) in T-cell lymphoma, 27:367  
  ins(7;13) in CLL, 24:143  
  ins(11;21) in MDS, 27:42  
In situ hybridization  
  at 20p12 in MEN-II, 24:129  
  c-Ha-ras-1 in M2 and CML, 29:191  
  c-met, 26:187  
  c-mos localization, 24:137  
  c-sis in neurofibromatosis, 25:169  
  P-glycoprotein, 26:187  
  ring (22) in neurofibromatosis, 25:169  
Inversion  
  inv(5) in MDS, 29:171  
  inv(7), inv(14) and fragile sites, 25:95  
  inv(12) constitutional, 24:345  
  inv(12) in malignancies, 28:113  
  inv(12)(p11q14) in DNS, 24:38, 39  
  inv(16) in a biphenotypic leukemia lacking monocytic markers, 25:367  
  inv(16) in AMoL (M5b), 26:309  
  inv(16) in colon cancer, 27:171  
  inv(16) in eosinophils of M4, 29:327  
  inv(16) in M4 in XY/XYY, 29:331  
  inv(16) in t-ANLL, 27:167  
  inv(16)(p13q22), fra(16)(q22) in ANLL, 25:81  
  #16 in AMMoL (M4), 24:257; 25:367; 26:309; 29:327  
Isochromosomes  
  hematologic diseases, 25:47  
  i(p) in duplicate in MDP, 29:319  
  i(7q), i(11q), i(17q) and i(21q), 25:47  
  i(12p) in dysgerminoma, 26:355  
  i(12P) in ovarian tumors, 26:355  
  i(17q) in lymphoma, 25:55  
  9p in PNH, 25:259  
  11q in Ewing's sarcoma, 25:97  
Karyotype(s)  
  adrenal cancer, 26:271  
  evolution in brain tumors (gliomas), 24:163  
  evolution in lymphoma, 24:271  
  evolution in M4 with inv(16), 24:257  
  evolution in PV, 25:243  
  in AML, 25:329  
  in ANLL, 25:329; 29:9  
  in astrocytomas, 29:201  
  in bladder cancer, 29:29  
  in blastic crisis of CML, 26:39  
  in breast cancer, 24:45; 27:289  
  in CLL, 25:109; 26:75; 28:93  
  in CML, 24:281; 25:75, 267, 329  
  in colorectal tumors, 29:289  
  in gastric cancer, 24:63  
  in gliomas, 24:163; 29:223  
  in HeLa cell line, 28:301  
  in hematologic malignancies, 24:143; 25:329  
  in lymphoma, 24:271; 25:223, 27:335; 28:267  
  in MDS, 25:329; 27:39  
  in myeloproliferative diseases, 24:143, 151; 25:329  
  in neuroectodermal tumor cell line, 24:75

Karyotype(s) con't  
 in peripheral neuroepithelioma, 24:119  
 in polycythemia vera, 25:233  
 in secondary lymphoma, 24:7  
 in Sézary syndrome, 27:79  
 in somatic cell hybrids (mouse), 24:95  
 meningioma, 26:127; 27:145  
 neurofibroma, 26:157  
 ovarian tumors, 26:327, 339, 355  
 prostate cancer, 26:165  
 renal cancer, 26:253  
 T-cell lymphoma, 28:267

Kidney; *see also* Renal cell carcinoma  
 telomeric association, 28:363  
 tumors, embryonal origin, 24:189  
 3p in renal cell carcinoma, 25:179; 26:253, 363  
 3p- as only change, 26:363  
 3p12-14 in, 26:253, 363

Klinefelter syndrome  
 acute leukemia, 26:375  
 hematologic disorders, 24:345  
 neoplasia in, 25:191

Large bowel  
 cancer, 24:11  
 cancer in black family, 24:11  
 carcinoid cell line, 24:17  
 mucinous adenocarcinoma, 24:11  
 noninvolvement of fragile site 10q24.2 in rectal cancer, 25:1

Lipogenic tumors; *see also* Adipose tissue tumors  
 cytogenetics, 24:319; 28:137  
 liposarcoma, 28:137  
 rings in, 24:319

Liposarcoma  
 chromosome changes, 28:137  
 myxoid with t(12;16), 26:185  
 t(12;16), 26:185; 28:137

Lung  
 adenocarcinoma cell lines, 26:317  
 adenocarcinomas (metastatic), with 3p-, 25:355  
 cancer, oncogene studies, 27:45  
 loss of heterozygosity at 3p21 in cancer, 27:361  
 small cell cancer, 27:45  
 3p- in lung cancers, 25:355; 27:45, 361

Lymph nodes  
 in lymphoma, 25:219  
 -Y in, 25:219

Lymphocytes  
 chromosome changes in, 24:33; 25:303  
 cyclophosphamide effects, 29:239  
 dysplastic nevus syndrome (DNS), 24:33, 299

fragile sites, 26:95  
 malignant melanoma patients, 24:299  
 proportions of B and T in culture, 29:151  
 SCE in 24:33  
 thyroid cancer patients, 25:303

Lymphoid hyperplasia  
 atypical, 27:251  
 cytogenetics in atypical, 27:251  
 molecular studies in, 27:251  
 t(2;19) in, 27:251

Lymphoma  
 Abelson virus induced in mouse cells, 28:119  
 Burkitt type translocation, 24:225  
 cell kinetics, 28:357  
 chromosome changes in secondary, 24:7  
 cutaneous T-cell, 28:267  
 cytogenetic findings, 25:55; 27:335  
 diffuse large cell with t(2;8), 24:225  
 in transplant recipient, 24:7  
 indolent, 27:335  
 isochromosomes, i(7q), i(11q), i(17q) and i(21q), 24:47  
 karyotypic evolution in, 24:271  
 Kiel classification, 25:56  
 molecular studies in, 27:191  
 prognostic implication of chromosomes changes, 25:55  
 secondary?, 24:7  
 Sézary syndrome, 27:79  
 T-cell, 28:267  
 t(14;18) in, 25:55, 219  
 -Y in, 25:219  
 +3, +7, +12, 1p+, 14q+, 6q-, i(17q) in lymphoma, 25:55  
 +12 in AIDS, 29:245

Malignant histiocytosis  
 7q-, 28:353

Malignant melanoma; *see* Melanoma

Markers  
 alph-L-fucosidase in hereditary ovarian cancer, 25:247  
 cell surface in CML, 26:25  
 esterase D in retinoblastoma, 27:27  
 hydatidiform moles, 26:143  
 lipid associated sialic acid, 25:247

Megakaryoblastic leukemia  
 chromosome changes, 25:259  
 evolution from PNH, 25:259  
 possible (transient) in Down's syndrome, 28:373

Melanoma  
 chromosome changes in Syrian hamster, 25:123  
 cytogenetics, 24:299

dysplastic nevus syndrome, 24:33, 299  
mouse, 22:81  
transplantable, 25:123

Mendelian  
mutations and cancer, 26:85

Meningioma  
clinical significance of chromosome changes, 26:127  
cytogenetic studies, 26:127; 27:145  
recessive genes, 27:145

Mesothelioma  
cytogenetic findings, 29:75

Methods  
analysis of bladder tumor biopsies, 29:103  
BrdU and cell synchronization, 28:229  
chromosomes in bladder cancer, 29:23, 103  
cytogenetic analysis of colonies, 24:1  
fluorodeoxyuridine synchronization, 24:1  
G-banding, 28:229  
hematopoietic colonies, 24:1  
immunoenzymatic staining, 27:229  
marrow analysis, 28:229  
ovarian tumors, 27:9  
simultaneous demonstration of chromosomes and cell surface markers, 27:229  
solid tumors, 27:9

Mitogens  
cytochalasin B and EBV, 28:93  
for B-cells, 24:109; 28:93

Mitotic  
recombination and tumors, 27:5

Mole(s); see Hydatidiform mole

Molecular studies  
amplification of N-myc, 26:235  
bcr in CML, 29:1  
bcr in CML cell lines, 25:271  
bcr in masked Ph in CML, 25:15; 26:105; 27:21  
c-Ha-ras-1 in M2 and CML, 29:191  
carcinoid cell line, 24:17  
in atypical lymphoid hyperplasia, 27:251  
in Bloom's syndrome cell lines, 26:287  
in cancer, 28:163  
in CML, 26:15, 105; 27:349  
in CML cell lines (EM-2 and EM-3), 25:271  
in erythroleukemia cell line, 28:301  
in lung cancer, 27:45, 361  
in lymphoma, 27:191  
in MEN-II, 24:129  
in mouse leukemia cells, 29:109  
in neuroblastoma, 26:235  
in osteogenic sarcoma, 29:303  
in peripheral neuropithelioma, 24:119  
in PLL, 27:89  
N-myc in neuroblastoma, 26:235  
of *fms* in ALL cell line, 25:341  
of heterozygosity, 28:335  
oncogene activity in CML, 26:15  
P-glycoprotein locus on 7q36; 25:141  
recombination and malignancy, 26:95  
reiterated DNA sequences, 28:163  
restriction endonucleases and marker chromosomes, 24:367  
retroviral activity in CML, 26:15  
with *c-mos* in t(8;21), 24:137  
+ 12 in CLL, 28:185

Mouse  
cell lines, 24:95; 25:317  
chromosome changes in mammary cancer cell line, 25:317  
cytogenetics of cell lines, 24:95; 25:317  
cytogenetics of leukemia cells, 29:109  
double minutes in cell lines, 25:317  
melanoma (B16-F10), 29:81  
rDNA in mouse leukemia cells, 29:109  
somatic cell hybrids, 24:95

Müllerian tumor  
ovary, 26:355

Multiple endocrine neoplasia syndrome (MEN-II)  
changes in blood lymphocytes, 25:303; 28:253  
chromosome analysis in, 24:129; 28:253  
chromosome 20, 27:327; 28:253  
del (20) p12.2, 24:129; 28:253  
DNA analysis in, 24:129  
DNA markers on chromosome 20, 27:327  
linkage analysis, 27:327  
Type II, 24:129; 26:85; 28:253  
13q RFLP, 29:183

Multiple myeloma; see Myeloma

Myelodysplastic syndromes (MDS)  
cell kinetics, 28:357  
chromosome changes, 24:145; 25:329; 26:199, 227; 27:39  
clinical, morphologic and cytogenetic correlations, 26:227  
constitutional chromosome changes, 24:345  
cytogenetics in siblings with MDS, 27:241  
deletions in, 26:227; 27:39  
+ der(21) in RA with excess blasts, 25:175  
drug induced, 26:213  
high platelet count and t(3;8), 27:1  
idic(X) in, 27:215

(MDS) con't  
 inv(5q) in secondary MDS, 29:171  
 inv(12), 28:113  
 iron stores in, 27:39  
 normal karyotypes, 25:161  
 Ph-positive, 26:213  
 phenylbutazone-induced, 26:213  
 RA with excess of blasts, 25:175; 26:199  
 RAEB and t(6;9), 29:135  
 refractory anemia, 24:159; 26:199  
 refractory anemia with -2 and DM, 28:367  
 rheumatoid arthritis, 25:161  
 secondary, 26:65  
 siblings with, 27:241  
 t(1;3), 28:277  
 t(1;7), a correction, 25:187  
 t(1;7) in CMMoL, 24:355  
 t(3;8) with high platelet count, 27:1  
 t(5;20) and 17p+ in, 24:371  
 t(6;9), 29:135  
 t(7;11) in, 26:191  
 t(8;21) in RA with excess blasts, 25:175  
 5q-, 26:199  
 5q- in refractory anemia, 24:159; 26:199  
 + 9 in, 27:73  
 11q- and iron stores, 27:39  
 13q14 in, 24:143  
 13q14 loss, 28:181  
 + 14 in RAEB, 29:315

Myelofibrosis; see also Myeloproliferative diseases (MPD)  
 in Ph-positive CML, 25:361  
 t(1;3) in, 25:361

Myeloid metaplasia; see  
 Myeloproliferative disorders

Myeloma, multiple  
 C-bands, 28:101  
 chromosome findings, 25:309, 375  
 t(14;18) in, 25:375  
 1q-, 2p+, 2q+, 7q-, 7p- in, 25:309

Myeloproliferative disorders (MPD)  
 blastic transformation of MMM, 24:221  
 chromosome changes, 24:145, 151  
 chromosome 7, 26:209  
 constitutional chromosome changes, 24:345; 25:87  
 constitutional t(3;6) in myelofibrosis, 25:87  
 cytogenetic studies, 24:151  
 eosinophilic, 26:209  
 i(17q) in myelofibrosis with myeloid metaplasia, 24:221  
 in myeloid metaplasia, 24:151  
 inv(12), 28:113  
 iso(9p) in duplicate, 29:319  
 MMM-published cases with blastic phase, 24:223

myelofibrosis, 24:151  
 secondary MMM, 26:65  
 t(1;7), a correction, 25:187  
 + 9 in, 27:73  
 13q14 in, 24:143

Nasopharyngeal cancer  
 genetic predisposition, 26:261  
 in vitro hyperdiploidy, 26:261

Near-haploid (y)  
 conversion in CML, 24:335

Neoplasia  
 cryptorchidism, 25:191  
 gonadal dysgenesis, 25:191  
 pseudohermaphroditism, 25:191

Neurinoma(s)  
 cytogenetic analysis, 28:187

Neuroblastoma  
 chromosome changes and prognosis, 29:175  
 cytogenetics of, 26:235  
 disseminated, 26:235  
 N-myc in, 26:235  
 oncogene (N-myc) amplifications, 26:235  
 prognosis and cytogenetics, 29:175

Neuroectodermal tumors  
 cell line, 24:75  
 chromosomal changes, 24:75  
 peripheral neuroepithelioma, 24:119  
 primitive, 24:75  
 1q+ or +1 in, 24:75  
 - 13 in, 24:75

Neuroepithelioma  
 c-sis translocation, 24:119  
 peripheral, 24:119

Neurofibromatosis  
 and polyposis coli, 28:245  
 c-sis studies, 25:169  
 cytogenetic clones, 26:157  
 in situ hybridization, 25:169  
 recurrent, 26:157  
 ring(22), 25:169

Non-Hodgkin lymphoma; see Lymphoma

Nucleolar organizer regions (NOR)  
 cistrons (rDNA) in mouse leukemia lines, 29:109  
 in bone marrow cells, 25:65  
 in CML, 25:131  
 Philadelphia chromosome, 25:131  
 rRNA amplification, 29:119

Nude mouse passage  
 ovarian cancer cells, 28:201

Oncogene(s)  
 abl and sis in CML, 26:15  
 abl, erb B, myc and Ha-ras in glioblastoma cell line, 25:285  
 activity in CML, 26:15  
 c-abl and c-myc in CML, 27:349

C-Ha-ras expression in leukemia cell line, 28:301  
c-Ha-ras-1 in M2 and CML, 29:191  
c-met, 26:187  
c-mos in t(8;21), 24:137  
c-mos locus, 24:137  
c-myc amplification in human leukemia cell line (HL-60), 28:127  
c-myc overexpression in PLL, 27:89  
c-sis in neurofibromatosis, 25:169  
c-sis in peripheral neuroepithelioma, 24:119  
cytosine-arabinoside effect on c-myc, 27:89  
expression in Bloom's syndrome cell lines, 26:287  
expression in glioblastoma cell line, 25:285  
fms in ALL with 5q-, 25:341  
in lung cancer (Ha-ras, Ki-ras, N-ras, myb, and myc), 27:45  
in lymphoma, 27:191  
localization of C-Ha-ras-1 in M2 and CML, 29:191  
N-myc amplification in neuroblastoma, 26:235  
retroviral activity in CML, 26:15  
translocation of c-sis, 24:119

Osteosarcoma  
cell line, 24:327  
esterase D expression, 24:327  
in patient with retinoblastoma, 28:335  
platelet derived growth factor, 29:303  
#13 in, 24:327; 28:335

Ovarian  
alpha-L-fucosidase variant, 25:247  
carcinoma cell lines, 24:231; 26:339, 28:201  
cytogenetic findings, 24:231; 26:327, 339, 355; 28:201  
dysgerminoma, 26:327, 355  
hereditary cancer, 25:247  
lipid associated sialic acid, 25:247  
Müllerian tumor, 26:355  
nude mouse passage, 28:201  
tumors, 26:327, 355  
tumors in sex chromosome disorders, 25:191  
1, 3 and 6 in, 26:339, 355  
1, 3, 6, 6, 11, and 14, 26:355

Pancreas  
cytogenetics of anaplastic carcinoma, 29:253

Paroxysmal nocturnal hemoglobinuria (PNH)  
chromosome changes, 25:259  
evolving into megakaryoblastic leukemia, 25:259  
subclonal evolution, 25:259  
t(7;11) in, 26:191

Ph chromosome; see Philadelphia chromosome and translocation

Philadelphia (Ph) chromosome and translocation  
atypical t(9;12;22), 25:183  
bcr in masked Ph, 25:15; 26:105; 27:21  
bcr studies, 25:271; 26:105; 27:349; 29:1, 57  
complex in, 27:375  
complex translocations, 24:281; 25:75  
DNA studies, 25:271  
duplication, 29:57  
four Ph chromosomes in CML, 28:179  
in CML, 24:281; 25:75, 165, 267; 27:375  
in drug induced MDS, 26:213  
in near-haploid line, 24:335  
in thrombocythemia, 25:227  
lymphoid blast crisis in thrombocythemia, 25:227  
masked Ph, 24:281; 25:15, 165; 26:42; 27:21  
masked Ph in blast crisis, 26:42  
NOR, 25:131  
t(5;22;9), 24:281; 25:15  
t(8;9;22), 24:281  
t(9;9;22;11), 24:281  
variant, 25:267; 26:105; 27:375

Plasma cell  
cytogenetics of cell lines, 27:135  
lines, 27:135

Platelet-derived growth factor  
composition, 29:303  
gene localization, 29:303  
in osteogenic sarcoma, 29:303

Pleomorphic adenoma  
cytogenetics, 28:237  
polyclonal chromosome evolution, 28:237  
with marker similar to one in endometrial cancer, 27:177  
with t(3;8;8), 27:177

Polycythemia vera (PV)  
chromosomes in, 25:233  
chromosomes 5 and 7, 25:233  
inv(12), 28:113  
secondary ANLL or MDS, 26:65  
+ 8, + 9, 13q-, 20q-, 25:233

Polymorphism(s)  
C-bands in ovarian and breast cancer, 28:77  
of C-bands in CML, 27:33  
of Y in boys with various tumors, 24:351  
of Y in CML, 24:295

Polyposis coli  
and neurofibromatosis, 28:245

Polyposis coli con't  
 extracolonic manifestations, 27:319  
 familial, 27:319; 28:245

Pre-B ALL  
 t(1;19) in, 25:379

Preleukemia  
 5q- in, 26:199

Premature chromosome condensation (PCC); see also Prophasing  
 and prophasing, 27:181  
 in acute leukemia, 27:51, 63  
 in breast cancer, 24:52  
 in cervical carcinoma, 24:263  
 methodology, 27:51, 63  
 relapse prediction, 27:51, 63

Probes  
 bcr in CML cell lines, 25:271  
 c-mos, 24:137  
 in lymphomas, 27:191  
 molecular, 27:191  
 p446, 24:24

Prognostic implications  
 cytogenetic findings in lymphoma, 25:55  
 cytogenetics in CLL, 25:119

Polymphocytic leukemia (PLL)  
 acquired Robertsonian translocation, 25:293  
 c-myc overexpression, 27:89  
 cytosine-arabinoside therapy effect, 27:89

Prophasing  
 definition, 27:181  
 in acute leukemia, 27:51, 63  
 in breast cancer, 24:52  
 in cervical cancer, 24:263  
 methodology, 27:51, 63  
 relapse predictor, 27:51, 63

Prostate  
 cancer, 26:165  
 cell line (xenografted), 26:165  
 karyotypic analysis, 26:165  
 small cell carcinoma, 26:165  
 tumors, embryonal origin, 24:189

Protooncogene; see Oncogenes

Pseudohermaphroditism  
 female, 25:191  
 genetic forms, 25:191  
 male, 25:191  
 testicular tumors, 25:191

Pseudo-Pelger-Huet anomaly  
 chromosome 17, 25:265  
 i(17q), 25:265  
 in CML, 25:265

Rectal cancer; see also Large bowel and colon cancer  
 breakpoints in cancer, 25:7  
 chromosome changes, 29:289

noninvolvement of fragile site 10q24.2, 25:7

Refractory anemia  
 chromosomes changes in, 25:329; 26:199  
 late appearing marker, 24:159  
 t(2;11) in, 25:335  
 t(8;21) and + der(21) in RA, 25:175  
 with excess of blasts in transformation, 25:175; 26:199  
 5q-, 24:159; 26:199  
 + 8, 24:159  
 + 14 in RAEB, 29:315

Refractory anemia with excess of blasts (RAEB); see Refractory anemia and myelodysplastic syndromes

Renal cell carcinoma; see also Kidney  
 genetic mechanism for 3p change, 25:179  
 in von Hippel-Lindau, 27:345  
 recurrent 3p rearrangement, 25:179; 26:253, 369  
 telomeric association, 28:363  
 3p- as only change, 26:369  
 3p12-14 in, 26:253, 369

Restriction endonucleases  
 identification of marker chromosomes by, 24:367

Retinoblastoma  
 chromosome breakpoint, 27:27  
 del(13q), 27:27  
 esterase D, 27:27

Retrovirus  
 activity in CML, 26:15

Reviews  
 abnormal sex differentiation and neoplasia, 25:191

Rhabdomyosarcoma  
 alveolar, 25:373  
 chromosome changes in, 28:157  
 in Down's syndrome, 28:155  
 t(2;13) in, 25:371, 373

Rheumatoid arthritis  
 leukemia and MDS in, 25:161  
 normal karyotypes in acute leukemia and MDS, 25:161

Ring(s)  
 blastic phase of CML, 25:253  
 constitutional r(22) in  
 neurofibromatosis, 25:169  
 in a gastric cancer, 24:64  
 in breast cancer, 24:52  
 in CML in blastic phase, 25: 253  
 in lipogenic tumors, 24:319

Robertsonian translocation  
 acquired in leukemia, 25:293  
 prolymphocytic leukemia, 25:293  
 review (in cancer), 25:293  
 Table, 25:298

Salivary gland tumors  
benign, 28:237  
cytogenetic findings, 24:205; 28:237  
mixed, 24:205; 28:237  
polyclonal evolution, 28:237  
#8 in, 24:205; 28:237

Sarcoma  
Ewing with iso(11q), 25:97  
liposarcoma, 26:185; 28:137  
myxoid liposarcoma, 26:185  
osteosarcoma, 24:327  
rhabdomyosarcoma with t(2;13), 25:371, 373  
synovial, 26:179, 181

Second International Workshop on Chromosomes in Solid Tumors  
abstracts, 28:27-47  
editorial, 28:1  
historical, 28:5  
preface, 28:3  
summary, 28:49

Secondary hematologic disorders  
chromosome changes in 26:65  
MDS following phenylbutazone, 26:213  
Ph-chromosome in, 26:213  
Ph-positive CML, 28:173  
therapy and, 26:65, 213

Sexual differentiation  
abnormal, 25:191  
neoplasia, 25:191

Sézary syndrome  
cytogenetic studies in, 27:79

Shionogi carcinoma 115; *see* Mouse and cell lines

Silver banding; *see* Nucleolar organizer regions (NOR)

Sister chromatid exchange (SCE)  
cells of dysplastic nevus syndrome, 24:33  
effects of tobacco, 27:15  
in fibroblasts of DNS, 24:33  
in HL-60 cells, 27:311  
in HSR, 26:245  
in lymphocytes of DNS, 24:33  
in melanoma patients, 24:308  
in nonpolyposis colon cancer syndrome, 27:111

Solid tumors; *see also* Tumors  
cytogenetics, 26:177; 28:1-47  
Second International Workshop, 28:1-47

Sperm  
"hot spot" in #1 of patient treated for Wilms tumor, 29:91

Stomach cancer  
cytogenetics in, 24:63  
#7 in, 24:63  
8q+ and i(8q), 24:63  
+ 9, i(9q) or 9p+ in, 24:63

#9 in, 24:63

Supernumerary nipples  
urologic malignancies, 24:185

Sweet syndrome  
acute leukemia with t(3;5), 28:87

Synchronization  
fluorodeoxyuridine, 24:1  
hematopoietic colonies, 24:1

Synovial sarcoma  
chromosome change, 26:179, 181  
t(X;18), 26:179, 181; 29:179

T-cell(s)  
CLL in AT, 26:217  
cutaneous lymphoma, 28:267  
in PHA-stimulated lymphocyte cultures, 29:151  
ins (6;11) in lymphomas, 27:367  
leukemic cell receptors, 28:327  
molecular studies, 27:251  
receptors, 28:327  
Sézary syndrome, 27:79

Techniques; *see* Methods

Telomeric association  
in ALL, 24:87  
renal tumors, 28:363

Testicular  
t(13;14) carrier and tumor, 26:297  
tumor, 26:297, 303  
tumor (secondary lymphoma), 24:7  
tumors, embryonal origin, 24:189; 25:191  
tumors in sex chromosome anomalies, 25:191

Testicular feminization  
neoplasia in, 25:191

Tetraploidy  
in ALL, 29:129

Tetrasomy  
+ 8, + 8 in ANLL, 27:269

Thrombocytopenia  
constitutional chromosome changes, 24:345  
evolving into lymphoid blast crisis, 25:227  
in CML with chromosome 3 changes, 27:371  
long survival, 25:185  
Ph-positive, 25:227  
trisomy 1q, 25:185

Thrombocytosis  
+ 9, 27:73

Thyroid cancer  
cell line, 25:27  
cytogenetic studies in cell line, 25:27, 303  
lymphocytes of patients with, 25:303  
medullary, 25:27, 303

Tobacco  
SCE, 27:15

Transitional cell carcinoma  
ureter with + 7 and i(5p), 25:369  
+ 7 and i(5p) in, 25:369

Translocations  
in ALL, 26:59  
in ANLL, 26:51; 29:9  
in breast cancer, 27:289  
in lung adenocarcinoma cell lines, 26:317  
in lymphoma, 27:335; 28:267  
in meningioma, 26:127  
in mouse melanoma lines, 29:81  
in neurofibroma, 26:157  
in salivary gland tumors, 24:205; 28:237  
in secondary (treatment related) ANLL, 29:43  
in somatic cell hybrids (mouse), 24:95  
in synovial sarcoma, 26:179, 181  
other than Ph in CML, 25:73  
Robertsonian in cancer and leukemia, 25:298, 335  
t(1;1) in ALL, 24:91  
t(1;2) in ALL, 24:90  
t(1;2) in multiple myeloma, 25:309  
t(1;3) in MDS, 28:277  
t(1;3) in Ph-positive CML with myelofibrosis, 25:361  
t(1;4) in blastic phase CML, 25:28  
t(1;6) in breast cancer, 27:291  
t(1;6;13;22) in CML, 25:75  
t(1;7) in CMMoL, 24:355  
t(1;7) in MPD, 24:154  
t(1;7) in myeloma, 25:375  
t(1;7), a correction (MDS, ANLL, MPD), 25:187  
t(1;7;14) in meningioma, 27:145  
t(1;9) in MPD, 24:154  
t(1;9) in PV, 25:240  
t(1;9;22) Ph in CML, 27:375  
t(1;11) in AMMoL, 24:181  
t(1;11) in breast cancer, 27:293  
t(1;11) in dysplastic nevus syndrome (DNS), 24:39  
t(1;12) constitutional in ANLL, 24:345  
t(1;13) in ALL, 24:90  
t(1;13) in AML (M2), 24:243  
t(1;13) in colon cancer, 27:357  
t(1;13) in lymphoma, 25:223  
t(1;13;14) in CLL, 25:109  
t(1;16) in ALL, 24:90  
t(1;17) in blastic phase CML, 25:28  
t(1;17) in CLL, 25:109  
t(1;17) in MDS, 27:243  
t(1;19) in pre-B ALL, 25:379  
t(1;21) constitutional in MPD, 24:345  
t(1;22) in neurofibroma, 26:157  
t(2;2) in CML, 25:75  
t(2;7) in myeloma, 25:375  
t(2;7;14) in meningioma, 27:145  
t(2;8) in diffuse large cell lymphoma, 24:225  
t(2;10) in CLL, 25:109  
t(2;10) in renal cancer, 26:253  
t(2;11) in CML, 25:335  
t(2;11) in MDS, 27:42  
t(2;13) in rhabdomyosarcoma, 25:371, 373  
t(2;14) in CML, 25:75  
t(2;14) in dysplastic nevus syndrome (DNS), 24:39  
t(2;15) in AML (M2), 24:243  
t(2;15) in dysplastic nevus syndrome (DNS), 24:39  
t(2;15;17) in APL, 28:113  
t(2;19) in atypical lymphoid hyperplasia, 27:251  
t(2;19) in lymphoma, 25:223  
t(2;21) in CLL, 24:145  
t(2;21) in multiple myeloma, 25:309  
t(3;3) in CML, 25:75  
t(3;5) in ANLL, 28:261  
t(3;5) in CML, 25:75, 267  
t(3;5) in M2 in Sweet's syndrome, 28:87  
t(3;6) constitutional in ANLL, 24:345  
t(3;6) constitutional in family with hematologic malignancies, 25:87  
t(3;8) in CML, 25:75  
t(3;8) in dysplastic nevus syndrome (DNS) 24:39  
t(3;8) in MDS with high platelet count, 27:1  
t(3;8) in salivary gland tumors, 24:205  
t(3;8;8) in pleomorphic adenoma, 27:177  
t(3;12) in adrenal cancer, 26:217  
t(3;17) in CML, 25:75  
t(3;17) in dysplastic nevus syndrome (DNS), 24:39  
t(3;17) in MDS and ANLL, 26:199  
t(3;19) in CLL, 25:109  
t(3;20) in CML, 27:371  
t(3;21) in MPD, 24:154  
t(4;9;22) Ph in CML, 27:375  
t(4;11) in adrenal cancer, 28:343  
t(4;13;17) in CLL, 24:145  
t(4;14) constitutional in ALL, 24:345  
t(4;14) in meningioma, 26:127  
t(4;17) in acute leukemia, 28:327  
t(4;17) in dysplastic nevus syndrome (DNS), 24:38  
t(4;18) in CLL, 25:109  
t(4;22) masked Ph in CML, 25:165  
t(5;7) in dysplastic nevus syndrome (DNS), 24:38  
t(5;8) in ovarian tumor, 26:327

t(5;15) in lung cancer, 25:355  
t(5;18) in adrenal cancer, 26:271  
t(5;20) in MDS, 24:371  
t(5;22;9) in Ph translocation, 24:281; 25:15  
t(6;7) in dysplastic nevus syndrome, 24:39  
t(6;7) in neuroectodermal tumor cell line, 24:84  
t(6;9) in ANLL, 29:363  
t(6;9) in MDS, 26:135  
t(6;11) in M4, 26:351  
t(6;19;22) in T-cell CLL in AT, 26:217  
t(6;22) in PV, 25:241  
t(7;8) in salivary gland tumors, 24:205  
t(7;8;9) in salivary gland tumors, 24:205  
t(7;11) c-Ha-ras-1 in M2 and CML, 29:191  
t(7;11) in nonlymphocytic neoplasia, 26:191  
t(7;14) and fragile sites, 26:95  
t(7;14) in dysplastic nevus syndrome (DNS), 24:38  
t(7;19) in dysplastic nevus syndrome (DNS), 24:39  
t(7;19) in PV, 25:237  
t(7;22) in CML, 25:267  
t(8;9) in salivary gland tumors, 24:205  
t(8;9;22) in Ph translocation, 24:281  
t(8;9;22) variant Ph, 26:105  
t(8;12;14) in ALL (L3), 28:145  
t(8;13) in salivary gland tumors, 24:205  
t(8;14) in lymphoma, 24:271  
t(8;16) in AML (M2), 24:243  
t(8;16) in AMoL (M5a), 24:213  
t(8;16) in M4, 27:101  
t(8;19) in CML, 25:75  
t(8;21) in AML, 25:329  
t(8;21) in ANLL, 24:137  
t(8;21) in CML, 25:103  
t(8;21) in dysplastic nevus syndrome (DNS), 24:38  
t(8;21) in refractory anemia with excess of blasts, 25:175  
t(9;5;22) masked Ph, 26:105  
t(9;9;22;11) in Ph translocation, 24:281  
t(9;10) with inv(16) and M5b, 26:309  
t(9;11) in CML, 25:75, 267  
t(9;11) in meningioma, 26:127  
t(9;12;22) atypical Ph, 25:183  
t(9;12;22) in CML, 24:359  
t(9;13) in CLL, 24:145  
t(9;13;22) in CML, 24:145  
t(9;17) in dysplastic nevus syndrome (DNS), 24:39  
t(9;22) in MDS, 26:213  
t(9;22) masked Ph, 26:105  
t(10;11) in M5, 26:351  
t(10;13) in CLL, 24:145  
t(11;11) in breast cancer, 27:293  
t(11;12) constitutional in MPD, 24:345  
t(11;13) in CLL, 25:109  
t(11;14) in CLL, 24:145  
t(11;16) in MDS, 27:243  
t(11;17) in breast cancer, 27:291  
t(11;20) in myeloma, 25:375  
t(11;21) in MDS, 27:42  
t(11;22) in esthesioneuroblastoma, 29:155  
t(11;22) in peripheral neuropathelioma, 24:119  
t(11;22) in primary marrow disease, 28:377  
t(12;9;22) variant Ph, 26:105  
t(12;11) in hairy cell leukemia, 24:113  
t(12;16) in myxoid liposarcoma, 26:185  
t(12;21) in dysplastic nevus syndrome (DNS), 24:39  
t(12;22) in CML, 25:183  
t(13;14) constitutional in MDS, ALL, ANLL, 24:345  
t(13;15) in MPD, 24:154  
t(13;15) Robertsonian (acquired) in PLL, 25:293  
t(13;17) in CLL, 24:145  
t(13;19) in CLL, 25:109  
t(13;22) in CLL, 24:145  
t(14;14) and fragile sites, 26:95  
t(14;14) in AT, 26:217  
t(14;18) in lymphoma, 25:55, 219, 223; 27:339  
t(14;18) in myeloma, 25:375  
t(14;21) constitutional in ANLL, 24:345  
t(15;16) in dysplastic nevus syndrome, 24:39  
t(15;17) in APL, 28:113  
t(15;17) variant in APL in CML, 28:349  
t(15;20) in adrenal cancer, 26:271  
t(15;21) in MDS, 27:42  
t(15;21) Robertsonian in CML, 25:335  
t(16;17) in CLL, 25:109  
t(16;18) in PV, 25:238  
t(16;21) in CLL, 25:109  
t(17;18) in CML, 25:75, 267  
t(17;19) in CML, 25:75  
t(18;22) in meningioma, 27:145  
t(20;22) in CML, 25:183  
t(X;13) in CLL, 24:145  
t(X;15) in APL, 29:65  
t(X;18) in synovial sarcoma, 26:179; 29:179  
t(Y;9) in CML, 25:75  
t(Y;15) constitutional in MPD, 24:345  
t(Y;17) constitutional in MDS, 24:345  
tandem in mouse melanoma, 29:81

Transplantation  
marrow in CML, 26:5

Trisomy  
origin of + 12 in CLL, 28:185  
+ 4 in ANLL, 26:117, 171, 175  
+ 7 in malignant fibrous histiocytoma, 29:97  
+ 8 in refractory anemia, 24:159  
+ 8, + 8 in ANLL, 27:269  
+ 8, + 9 in PV, 25:233  
+ 9 and thrombocytosis, 27:73  
+ 9 in hematologic disorders, 27:73

Trophoblasts  
cytogenetics, 29:271  
from complete moles, 29:271

Tumors  
brain, 24:163; 26:127  
breast, 24:45  
carcinoid, 24:17  
cytogenetics, 26:177  
gastric, 24:63  
gliomas, 24:163  
lipogenic with ring, 24:327  
meningioma, 26:127  
mitotic recombination in, 27:5  
neuroectodermal, 24:75  
ovarian, 24:231; 26:327; 355  
polyclonal origin, 27:5  
salivary glands (mixed), 24:205; 28:237  
Second International Workshop, 27:1-47  
sex chromosome disorders, 25:191  
transplantable melanoma, 25:123  
urologic, 24:185, 189

Ureter  
transitional cell carcinoma, 25:369  
tumor with + 7 and i(5p), 25:369

Urologic cancer  
embryonal origin of tumors, 24:189  
supernumerary nipples, 24:185

Virus  
Abelson induced lymphoma in mouse lines, 28:119

Simian virus 40, 25:149  
transformation of amniocyte cell lines, 25:149

Von Hippel-Lindau disease  
renal cell carcinoma, 27:345  
3p- in renal cancer, 27:345

Waldenström's macroglobulinemia  
chromosome changes, 29:261

Wilms' tumor  
abnormal #1 in sperm of treated patients, 29:91  
constitutional "hot spot" in sperm of patient with, 29:91

X-chromosome  
anomalies and neoplasia, 25:191  
i dic(X) in MDS, 27:215  
t(X;15) in APL, 29:65  
t(X;18) in synovial sarcoma, 29:179  
XXX constitutional in ANLL, 24:345  
XXY and acute leukemia, 26:375  
XXY and neoplasia, 25:191  
XXY constitutional in MDS, ALL, MPD, 24:345  
45,XO and neoplasia, 25:191  
45,XO constitutional in AA, 24:345

Y chromosome  
constitutive heterochromatin in CML, 24:295  
heterochromatism in boys with various tumors, 25:351  
inv(16) in XY/XYY with M4, 29:331  
polymorphism in CML, 24:295  
XYY and AML, 24:363  
XYY constitutional in ANLL, ALL and ET, 24:345  
- Y in lymphoma, 25:219  
- Y in meningioma, 26:127

